<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0606210765
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VORIC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VORICONAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        295
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELPEN PHARMACEUTICALS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELPEN PHARMACEUTICALS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VORIC contains the active substance voriconazole. VORIC is an antifungal medicine. It works by killing or stopping the growth of the fungi that cause infections.<br />It is used for the treatment of patients (adults and children over the age of 2) with:<br />&bull; invasive aspergillosis (a type of fungal infection due to Aspergillus sp),<br />&bull; candidaemia (another type of fungal infection due to Candida sp) in non-neutropenic patients (patients without abnormally low white blood cells count),<br />&bull; serious invasive Candida sp. infections when the fungus is resistant to fluconazole (another antifungal medicine),<br />&bull; serious fungal infections caused by Scedosporium sp. or Fusarium sp. (two different species of fungi).<br />VORIC is intended for patients with worsening, possibly life-threatening, fungal infections.<br />Prevention of fungal infections in high risk bone marrow transplant recipients.<br />This product should only be used under the supervision of a doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take VORIC<br />- If you are allergic to the active ingredient voriconazole, or to Betadex Sulfobutyl Ether Sodium (listed in section 6).<br />It is very important that you inform your doctor or pharmacist if you are taking or have taken any other medicines, even those that are obtained without a prescription, or herbal medicines.<br />The medicines in the following list must not be taken during your course of VORIC treatment:<br />&bull; Terfenadine (used for allergy)<br />&bull; Astemizole (used for allergy)<br />&bull; Cisapride (used for stomach problems)<br />&bull; Pimozide (used for treating mental illness)<br />&bull; Quinidine (used for irregular heart beat)<br />&bull; Rifampicin (used for treating tuberculosis)<br />&bull; Efavirenz (used for treating HIV) in doses of 400 mg and above once daily<br />&bull; Carbamazepine (used to treat seizures)<br />&bull; Phenobarbital (used for severe insomnia and seizures)<br />&bull; Ergot alkaloids (e.g., ergotamine, dihydroergotamine; used for migraine)<br />&bull; Sirolimus (used in transplant patients)<br />&bull; Ritonavir (used for treating HIV) in doses of 400mg and more twice daily<br />&bull; St. John&rsquo;s Wort (herbal supplement)<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before taking VORIC if:<br />&bull; you have had an allergic reaction to other azoles.<br />&bull; you are suffering from, or have ever suffered from liver disease. If you have liver disease, your doctor may prescribe a lower dose of VORIC. Your doctor should also monitor your liver function while you are being treated with VORIC by doing blood tests.<br />&bull; you are known to have cardiomyopathy, irregular heart beat, slow heart rate or an abnormality of electrocardiogram (ECG) called &lsquo;long QTc syndrome&rsquo;.<br />You should avoid any sunlight and sun exposure while being treated. It is important to cover sun exposed areas of skin and use sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun&rsquo;s UV rays can occur. These precautions are also applicable to children.<br />While being treated with VORIC:<br />&bull; tell your doctor immediately if you develop<br />o sunburn<br />o severe skin rash or blisters<br />o bone pain<br />If you develop skin disorders as described above, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you to be seen on a regular basis. There is a small chance that skin cancer could develop with long-term use of VORIC.<br />Your doctor should monitor the function of your liver and kidney by doing blood tests.<br />Children and adolescents<br />VORIC should not be given to children younger than 2 years of age.<br />Other medicines and VORIC<br />Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including those that are obtained without a prescription.<br />Some medicines, when taken at the same time as VORIC, may affect the way VORIC works or VORIC may affect the way they work.<br />Tell your doctor if you are taking the following medicine, as treatment with VORIC at the same time should be avoided if possible:<br />&bull; Ritonavir (used for treating HIV) in doses of 100 mg twice daily<br />Tell your doctor if you are taking either of the following medicines, as treatment with VORIC at the same time should be avoided if possible, and a dose adjustment of voriconazole may be required:<br />&bull; Rifabutin (used for treating tuberculosis). If you are already being treated with rifabutin your blood counts and side effects to rifabutin will need to be monitored.<br />&bull; Phenytoin (used to treat epilepsy). If you are already being treated with phenytoin your blood concentration of phenytoin will need to be monitored during your treatment with VORIC and your dose may be adjusted.<br />Tell your doctor if you are taking any of the following medicines, as a dose adjustment or monitoring may be required to check that the medicines and/ or VORIC are still having the desired effect:<br />&bull; Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol; used to slow down clotting of the blood)<br />&bull; Ciclosporin (used in transplant patients)<br />&bull; Tacrolimus (used in transplant patients)<br />&bull; Sulphonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)<br />&bull; Statins (e.g., atorvastatin, simvastatin) (used for lowering cholesterol)<br />&bull; Benzodiazepines (e.g midazolam, triazolam) (used for severe insomnia and stress)<br />&bull; Omeprazole (used for treating ulcers)<br />&bull; Oral contraceptives (if you take VORIC whilst using oral contraceptives, you may get side effects such as nausea and menstrual disorders)<br />&bull; Vinca alkaloids (e.g., vincristine and vinblastine) (used in treating cancer)<br />&bull; Indinavir and other HIV protease inhibitors (used for treating HIV)<br />&bull; Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (used for treating HIV) (some doses of efavirenz can NOT be taken at the same time as VORIC)<br />&bull; Methadone (used to treat heroin addiction)<br />&bull; Alfentanil and fentanyl and other short-acting opiates such as sufentanil (painkillers used for surgical procedures)<br />&bull; Oxycodone and other long-acting opiates such as hydrocodone (used for moderate to severe pain)<br />&bull; Non-steroidal anti-inflammatory drugs (e.g., ibuprofen, diclofenac) (used for treating pain and inflammation)<br />&bull; Fluconazole (used for fungal infections)<br />&bull; Everolimus (used for treating advanced kidney cancer and in transplant patients)<br />Pregnancy and breast-feeding<br />VORIC must not be used during pregnancy, unless indicated by your doctor. Effective contraception must be used in women of childbearing potential. Contact your doctor immediately if you become pregnant while being treated with VORIC.<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br />Driving and using machines<br />VORIC may cause blurring of vision or uncomfortable sensitivity to light. While affected, do not drive or operate any tools or machines. Tell your doctor if you experience this.<br />VORIC contains sodium<br />This medicinal product contains 222mg sodium per vial. To be taken under consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you.</p><p>Check with your doctor if you are not sure. Your doctor will determine your dose depending on your weight and the type of infection you have.<br />Your doctor may change your dose depending on your condition.<br />The recommended dose for adults (including elderly patients) is as follows:<br />Intravenous<br />Dose for the first 24 hours (Loading Dose)<br />6 mg/kg every 12 hours for the first 24 hours<br />Dose after the first 24 hours (Maintenance Dose)<br />4 mg/kg twice a day<br />Depending on your response to treatment, your doctor may decrease the dose to 3 mg/kg twice daily.<br />The doctor may decide to decrease the dose if you have mild to moderate cirrhosis.<br />Use in children and adolescents<br />The recommended dose for children and teenagers is as follows:<br />Intravenous<br />Children aged 2 to less than 12 years and teenagers aged 12 to 14 years weighing less than 50 kg<br />Teenagers aged 12 to 14 years weighing 50 kg or more; and all teenagers older than 14<br />Dose for the first 24 hours (Loading Dose)<br />9 mg/kg every 12 hours for the first 24 hours<br />6 mg/kg every 12 hours for the first 24 hours<br />Dose after the first 24 hours (Maintenance Dose)<br />8 mg/kg twice a day<br />4 mg/kg twice a day<br />Depending on your response to treatment, your doctor may increase or decrease the daily dose.<br />VORIC Lyophilized for injection will be reconstituted and diluted to the correct concentration by your hospital pharmacist or nurse. (Please refer to the end of this leaflet for further information)<br />This will be given to you by intravenous infusion (into a vein) at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.<br />If you or your child are taking VORIC for prevention of fungal infections, your doctor may stop giving VORIC if you or your child develop treatment related side effects.<br />If a dose of VORIC has been forgotten:<br />As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.<br />If you stop taking VORIC:<br />VORIC treatment will continue for as long as your doctor advises, however duration of treatment with VORIC Lyophilized for injection should be no more than 6 months.<br />Patients with a weakened immune system or those with difficult infections may require long-term treatment to prevent the infection from returning. You may be switched from the intravenous infusion to tablets once your condition improves.<br />When VORIC treatment is stopped by your doctor you should not experience any effects.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If any side effects occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.<br />Serious side effects &ndash; Stop taking VORIC and see a doctor immediately<br />&bull; Rash<br />&bull; Jaundice; Changes in blood tests of liver function<br />&bull; Pancreatitis<br />Other side effects<br />Very common: may affect more than 1 in 10 people<br />&bull; Visual impairment (change in vision including blurred vision, visual color alterations, abnormal intolerance to visual perception of light, colour blindness, eye disorder, halo vision, night blindness, swinging vision, seeing sparks, visual aura, visual acuity reduced, visual brightness, loss of part of the usual field of vision, spots before the eyes)<br />&bull; Fever<br />&bull; Rash<br />&bull; Nausea, vomiting, diarrhoea<br />&bull; Headache<br />&bull; Swelling of the extremities<br />&bull; Stomach pains<br />&bull; Breathing difficulties<br />&bull; Elevated liver enzymes<br />Common: may affect up to 1 in 10 people<br />&bull; Inflammation of the sinuses, inflammation of the gums, chills, weakness<br />&bull; Low numbers of some types, including severe, of red (sometimes immune-related) and/or white blood cells (sometimes with fever), low numbers of cells called platelets that help the blood to clot<br />&bull; Allergic reaction or exaggerated immune response<br />&bull; Low blood sugar, low blood potassium, low sodium in the blood<br />&bull; Anxiety, depression, confusion, agitation, inability to sleep, hallucinations<br />&bull; Seizures, tremors or uncontrolled muscle movements, tingling or abnormal skin sensations, increase in muscle tone, sleepiness, dizziness<br />&bull; Bleeding in the eye<br />&bull; Heart rhythm problems including very fast heartbeat, very slow heartbeat, fainting<br />&bull; Low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)<br />&bull; Acute breathing difficulty, chest pain, swelling of the face (mouth, lips and around eyes), fluid accumulation in the lungs<br />&bull; Constipation, indigestion, inflammation of the lips<br />&bull; Jaundice, inflammation of the liver and liver injury<br />&bull; Skin rashes which may lead to severe blistering and peeling of the skin characterized by a flat, red area on the skin that is covered with small confluent bumps, redness of the skin<br />&bull; Itchiness - Hair loss<br />&bull; Back pain<br />&bull; Kidney failure, blood in the urine, changes in kidney function tests<br />Uncommon: may affect up to 1 in 100 people<br />&bull; Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels<br />&bull; Inflammation of the thin tissue that lines the inner wall of the abdomen and covers the abdominal organ<br />&bull; Enlarged lymph glands (sometimes painful), failure of blood marrow, increased eosinophil<br />&bull; Depressed function of the adrenal gland, underactive thyroid gland<br />&bull; Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet<br />&bull; Problems with balance or coordination<br />&bull; Swelling of the brain<br />&bull; Double vision, serious conditions of the eye including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve resulting in vision impairment, optic disc swelling<br />&bull; Decreased sensitivity to touch<br />&bull; Abnormal sense of taste<br />&bull; Hearing difficulties, ringing in the ears, vertigo<br />&bull; Inflammation of certain internal organs- pancreas and duodenum, swelling and inflammation of the tongue<br />&bull; Enlarged liver, liver failure, gallbladder disease, gallstones<br />&bull; Joint inflammation, inflammation of the veins under the skin (which may be associated with the formation of a blood clot)<br />&bull; Inflammation of the kidney, proteins in the urine, damage to the kidney<br />&bull; Very fast heart rate or skipped heartbeats, sometimes with erratic electrical impulses<br />&bull; Abnormal electrocardiogram (ECG)<br />&bull; Blood cholesterol increased, blood urea increased<br />&bull; Allergic skin reactions (sometimes severe), including life-threatening skin condition that causes painful blisters and sores of the skin and mucous membranes, especially in the mouth, inflammation of the skin, hives, sunburn or severe skin reaction following exposure to light or sun, skin redness and irritation, red or purple discoloration of the skin which may be caused by low platelet count, eczema<br />&bull; Infusion site reaction<br />Rare: may affect up to 1 in 1000 people<br />&bull; Overactive thyroid gland<br />&bull; Deterioration of brain function that is a serious complication of liver disease<br />&bull; Loss of most fibres in the optic nerve, clouding of the cornea, involuntary movement of the eye - Bullous photosensitivity<br />&bull; A disorder in which the body&rsquo;s immune system attacks part of the peripheral nervous system<br />&bull; Heart rhythm or conduction problems (sometimes life threatening)<br />&bull; Life threatening allergic reaction<br />&bull; Disorder of blood clotting system<br />&bull; Allergic skin reactions (sometimes severe), including rapid swelling (oedema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or sore patches of thick, red skin with silvery scales of skin, irritation of the skin and mucous membranes, life-threatening skin condition that causes large portions of the epidermis, the skin&rsaquo;s outermost layer, to detach from the layers of skin below<br />&bull; Small dry scaly skin patches, sometimes thick with spikes or &lsquo;horns&rsquo;<br />Side effects with frequency not known:<br />&bull; Freckles and pigmented spots<br />Other significant side effects whose frequency is not known, but should be reported to your doctor immediately:<br />&bull; Skin cancer<br />&bull; Inflammation of the tissue surrounding the bone<br />&bull; Red, scaly patches or ring-shaped skin lesions that may be a symptom of an autoimmune disease called cutaneous lupus erythematosus<br />Reactions during the infusion have occurred uncommonly with VORIC (including flushing, fever, sweating, increased heart rate and shortness of breath). Your doctor may stop the infusion if this occurs.<br />As VORIC has been known to affect the liver and the kidney, your doctor should monitor the function of your liver and kidney by doing blood tests. Please advise your doctor if you have any stomach pains or if your stools have a different consistency.<br />There have been reports of skin cancer in patients treated with VORIC for long periods of time.<br />Sunburn or severe skin reaction following exposure to light or sun was experienced more frequently in children. If you or your child develops skin disorders, your doctor may refer you to a dermatologist, who after consultation may decide that it is important for you or your child to be seen on a regular basis. Elevated liver enzymes were also observed more frequently in children.<br />If any of these side effects persist or are troublesome, please tell your doctor.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.<br />&bull; Saudi Arabia:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&bull; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356- 2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p><br />&bull; Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.<br />Do not store above 30&deg;C.<br />Store in the original package in order to protect from light.<br />After reconstitution<br />Store in a refrigerator (2&deg;C - 8&deg;C)<br />Once reconstituted, VORIC should be used immediately, but if necessary may be stored for up to 24 hours at 2&deg;C - 8&deg;C (in a refrigerator). Reconstituted VORIC needs to be diluted with a compatible infusion solution first before it is infused. (Please refer to the end of this leaflet for further information).<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer required. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;<br />The active substance is voriconazole.<br />Each vial contains 200 mg voriconazole, equivalent to a 10 mg/ml solution when reconstituted as directed by your hospital pharmacist or nurse (see the information at the end of this leaflet).<br />&bull; The other ingredient is Betadex Sulfobutyl Ether Sodium.<br />What Voric looks like and contents of the pack<br />Voric is presented in single use glass vials as a Lyophilized for injection.<br />Marketing Authorisation Holder<br />AJA Pharmaceutical Industries Company Ltd.<br />Hail Industrial City MODON, Street No 32<br />PO Box 6979, Hail 55414, Kingdom of Saudi Arabia<br />Tel: +966 11 268 7900<br />Manufacturer<br />ELPEN Pharmaceutical Co. Inc.<br />95 Marathonos Ave., GR-19009 Pikermi Attica, Greece<br />This leaflet was last revised in (10/2020).</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center"><strong>This is a Medicament</strong><br />&bull; Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.<br />&bull; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.<br />&bull; The doctor and the pharmacist are the experts in medicines, their benefits and risks.<br />&bull; Do not by yourself interrupt the period of treatment prescribed for you.<br />&bull; Do not repeat the same prescription without consulting your doctor.<br />&bull; Keep all medicaments out of reach of children.</td></tr><tr><td style="text-align:center"><strong>Council of Arab Health Ministers<br />Union of Arab Pharmacists</strong></td></tr></tbody></table><p><br />---------------------------------------------------------------------------<br />The following information is intended for medical or healthcare professionals only:<br />Reconstitution and Dilution information<br />&bull; VORIC Lyophilized for injection needs to first be reconstituted with either 19 ml of Water for Injections or 19 ml of 9 mg/ml (0.9%) Sodium Chloride for Infusion to obtain an extractable volume of 20 ml of clear concentrate containing 10 mg/ml voriconazole.<br />&bull; Discard the VORIC vial if the vacuum does not pull the diluent into the vial.<br />&bull; It is recommended that a standard 20 ml (non-automated) syringe be used to ensure that the exact amount (19.0 ml) of Water for Injections or of 9 mg/ml (0.9%) Sodium Chloride for Infusion is dispensed.<br />&bull; The required volume of the reconstituted Lyophilized concentrate is then added to a recommended compatible infusion solution listed below to obtain a final VORIC solution containing 0.5 to 5 mg/ml of voriconazole.<br />&bull; This Lyophilized medicinal product is for single use only and any unused solution should be discarded and only clear solutions without particles should be used.<br />&bull; Not for administration as a bolus injection.<br />&bull; For storage information, please refer to Section 5 &lsquo;How to store VORIC&rsquo;.<br />Required Volumes of 10 mg/ml VORIC Concentrate</p><p><img alt="" width="487" height="728" src="data:image/png;base64,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" /></p><p>VORIC is a single dose unpreserved sterile lyophilized powder. Therefore, from a microbiological point of view, the reconstituted solution must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8&deg;C.<br />Compatible Infusion Solutions:<br />The reconstituted solution can be diluted with:<br />Sodium Chloride 9 mg/ml (0.9%) Solution for Injection<br />Compound Sodium Lactate Intravenous Infusion<br />5% Glucose and Lactated Ringer&rsquo;s Intravenous Infusion<br />5% Glucose and 0.45% Sodium Chloride Intravenous Infusion<br />5% Glucose Intravenous Infusion<br />5% Glucose in 20 mEq Potassium Chloride Intravenous Infusion<br />0.45% Sodium Chloride Intravenous Infusion<br />5% Glucose and 0.9% Sodium Chloride Intravenous Infusion<br />The compatibility of VORIC with diluents other than listed above (or listed below under &lsquo;Incompatibilities&rsquo;) is unknown.<br />Incompatibilities:<br />VORIC lyophilized powder must not be infused into the same line or cannula concomitantly with other drug infusions, including parenteral nutrition (e.g., Aminofusin 10% Plus).<br />Infusions of blood products must not occur simultaneously with VORIC.<br />Infusion of total parenteral nutrition can occur simultaneously with VORIC but not in the same line or cannula.<br />VORIC lyophilized powder must not be diluted with 4.2% Sodium Bicarbonate Infusion.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Voric is presented in single use glass vials as a Lyophilized for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />AJA Pharmaceutical Industries Company Ltd.<br />Hail Industrial City MODON, Street No 32<br />PO Box 6979, Hail 55414, Kingdom of Saudi Arabia<br />Tel: +966 11 268 7900</p><p><br /><strong>Manufacturer</strong><br />ELPEN Pharmaceutical Co. Inc.<br />95 Marathonos Ave., GR-19009 Pikermi Attica, Greece</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in (10/2020).
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فوريك على المادة الفعالة فوريكونازول. فوريك هو دواء مضاد للفطريات. ويعمل عن طريق قتل الفطريات المسببة لحالات العدوى أو إيقاف نموها.</p><p dir="RTL">يستخدم لعلاج المرضى (البالغين والأطفال أكبر من سنتين) المصابين بـ:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الرشاشيات الاجتياحي (نوع من أنواع العدوى الفطرية التي يسببها جنس الرشاشيات (اسبرجلس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء المبيضة في الدم (نوع آخر من العدوى الفطرية التي يسببها جنس المبيضات (كانديدا) في المرضى غير المصابين بنقص العدلات (النيتروفيلز) المرضى غير المصابين بانخفاض غير طبيعي في تعداد خلايا الدم البيضا).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى جنس المبيضات الخطيرة الاجتياحية عندما تكون الفطريات مقاومة للعلاج بفلوكونازول (دواء آخر مضاد للفطريات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;حالات العدوى الفطرية الخطيرة التي يسببها جنس البوغانة (سيدوسبوريوم) أو جنس الفطريات المغزلاوية (فيوزاريوم). (جنسان مختلفان من الفطريات).</p><p dir="RTL">فوريك مخصص للمرضى المصابين بحالات عدوى فطرية متفاقمة، يحتمل أن تكون مهددة للحياة.</p><p dir="RTL">منع الإصابة بحالات العدوى الفطرية في المرضى الذين خضعوا لعملية زرع نخاع العظم المعرضين لدرجة عالية من الخطر ينبغي تناول هذا المنتج فقط تحت إشراف الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فوريك في الحالات الآتية: </strong></p><p dir="RTL">إذا كنت مصاباً بالحساسية تجاه فوريكونازول أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">من المهم جداً أن تخبر طبيبك أو الصيدلي بأي أدوية أخرى تتناولها أو قد تناولتها في السابق، حتى تلك التي يتم الحصول عليها بدون وصفة طبية أو الأدوية العشبية.</p><p dir="RTL">يجب عدم تناول الأدوية المذكورة في القائمة الآتية خلال دورة علاجك بفوريك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيرفينادين (يستخدم لعلاج الحساسية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استيميزول (يستخدم لعلاج الحساسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (يستخدم لعلاج مشكلات المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيموزيد (يستخدم لعلاج الأمراض العقلية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (يستخدم لعلاج ضربات القلب غير المنتظمة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايفافيبربنز (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات تبلغ 400 ملجم فأكثر مرة واحدة يويماً</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربامازيبين (يستخدم لعلاج النوبات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينوباربيتال (يستخدم لعلاج الأرق الشديد والنوبات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الإرجوت (على سبيل المثال: ارجوتامين، وثنائي هيدرو إرجوتامين ؛ تستخدم لعلاج الصداع النصفي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس (يستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات تبلغ 400 ملجم فأكثر مرتين يومياً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (مكمل عشبي).</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث م طبيبك أو الصيدلي أو الممرضة قبل تناول فوريك إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت قد ظهرت عليك تفاعلات حساسية تجاه أي من الأدوية الأزولية الأ&times;رى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من، أو عانيت في السابق من مرض بالكبد إذا كنت مصاباً بمرض بالكبد. فقد يقوم طبيبك بوصف جرعة أقل من فوريك ينبغي على طبيبك أيضاً مراقبة وظائف كبدك أثناء خضوعك للعلاج بفوريك عن طريق إجراء فحوصات للدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من إصابة معروفة عضلة القلب أو ضربات قلب غير منتظمة أو معدل نبضات قلب بطئ أو خلل برسم القلب (ECG) يسمى متلازمة طول فترة َQT المصححة &quot;.</p><p dir="RTL">ينبغي عليك تجنب ضوء الشمس والتعرض لأشعة الشمس أثناء فترة علاجك من الضروري تغطية مناطق الجلد المعرضة لأشعة الشمس واستخدام واق من الشمس ذو عامل حماية (SPF) عال ؛ فقد تحدث زيادة في حساسية الجلد لأشعة الشمس فوق البنفسجية تنطبق هذه الاحتياطات أيضاً على الأطفال.</p><p dir="RTL">أثناء العلاج بفوريك</p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بأي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حروق الشمس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات شديدة من الطفح الجلدي أو البثور</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العظم</p><p dir="RTL">إذا أصبت بأي من اضطرابات الجلد المذكورة أعلاه، فقد يحيلك طبيبك إلى طبيب جلد، الذي قد يقرر بعد الاستشارة أهمية تكرار زيارتك له بشكل منتظم هناك احتمال ضئيل للإصابة بسرطان الجلد عند الاستخدام طويل الأمد لفوريك.</p><p dir="RTL">ينبغي على طبيبك مراقبة وظائف كبدك وكليتيك عن طريق إجراء فحوصات للدم.</p><p dir="RTL"><strong>الأطفال المراهقون </strong></p><p dir="RTL">ينبغي عدم إعطاء فوريك للأطفال الأصغر من عامين</p><p dir="RTL"><strong>الأدوية الأخرى وفوريك</strong></p><p dir="RTL">يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى، بما فيها تلك التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية بعد تناولها بالتزامن مع فوريك، على طريقة عمل فوريك أو قد يؤثر فوريك على طريقة عملها.</p><p dir="RTL">أخبر طبيبكإذا كنت تتناول الأدوية الآتية إذ ينبغي تجنب استعمالها بالتزامن مع العلاج بفوريك إذا أمكن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير (يستخدم لعلاج فيروس نقص المناعة البشرية) بجرعات قدرها 100 ملجم مرتين يومياً.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أي من الدوائين الآتيين، حيث ينبغي تجنب استعمالهما بالتزامن مع العلاج بفوريك إذا أمكن، ويمكن أن تكون هناك حاجة لتعديل جرعة فوريكونازول.</p><p dir="RTL">ريفابوتين (يستخدم لعلاج السل) إذا كنت تخضع بالفعل للعاج بريفابوتين، فستكون هناك حاجة لمراقبة تعداد مكونات دمك والآثار الجانبية المصاحبة لريفابوتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيتوين (يستخدم لعلاج الصرع) إذا كنت تخضع بالفعل لعلاج بريفابوتين، فستكون هناك حاجة لمراقبة تركيز فنيتوين في دمك أثناء علاجك بفوريك وقد يتم تعديل الجرعة المحددة لك.</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أياً من الأدويةا لآتية، إذ قد تكون هناك حاجة لتعديل الجرعة أو إجراء مراقبة للتحقق من أن الأدوية و / أو فوريك لا تزال تحدث التأثير المرغوب فيه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين ومضادات التجلط الأخرى (مثل فينوبروكومن، وأسينوكومارول، تستخدم لإبطاء تجلط الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (يستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (يستخدم لمرضى زراعة الأعضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلفونيليوريات (مثل تولبوتاميد، وجلييزيد، وجلوبيوريد) (تستخدم لعلاج داء السكري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستاتينات (مثل أتورفاستاتين، وسيمفاستاتين) (تستخدم لخفض الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنزوديازبيبنات (مثل ميدازولام، وتريازولام) (تستخدم لعلاج الأرق الشديد والتوتر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوميبر ازول (يستخدم لعلاج القرح)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موانع الحمل التي يتم تناولها عن طريق الفم (إذا تناولت فوريك أثناء استخدام موانع الحمل التي يتم تناولها عن طريق الفم، فقد تصابين بآثار جانبية مثل الغثيان واضطرابات الحيض).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الفينكا (مثل فينكريستين وفينبلاستين) (تستخدم في علاج السرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندينافير والمثبطات الأخرى لإنزيم بروتياز فيروس نقص المناعة البشرية (تستخدم لعلاج فيروس نقص المناعة البشرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المثبطات غير النيكليوزيدية لإنزيم المنتسخة العكسية (مثل إيفافيرينز، وديلافيردين، ونيفيرابين) (تستخدم لعلاج فيروس نقص المناعة البشرية) (بعض جرعات إيفافيرينز لا يمكن تناولها في نفس الوقت مع فوريك)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثادون (يستخدم لعلاج إدمان الهيروين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينتانيل وفينتانيل والأفيونات قصيرة المفعول الأخرى مثل سوفينتانيل (مسكنات الألم التي تستخدم في العمليات الجراحية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسيكودون وألأفيونات ممتدة المفعول الأخرى مثل هيدروكودون (تستخدم في الآلام المتوسطة إلى الشديدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (مثل إيبوبروفين، وديكلوفيناك) (تستخدم لعلاج الألم والالتهاب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول (يستخدم لحالات العدوى الفطرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفيروليموس (يستخدم لعلاج سرطان الكلى المتقدم ولمرضى زراعة الأعضاء).</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL">يجب عدم تناول فوريك أثناء الحمل، إذا أقر طبيبك ذلك يجب على السيدات القادرات على الإنجاب استخدام وسيلة فعالة لمنع الحمل. اتصلي بطبيك فوراً إذا أصبحت حاملاً اثناء تناولك لفوريك.</p><p dir="RTL">إذا كنت حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملاً أو تخططين للحمل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">يمكن لفوريك أن يسبب تغيماً في الرؤية أو حساسية غير مريحة تجاه الضوء. لا تقم بالقيادة أو تشغيل أي أدوات أو آلات بينما لا تزال تحت تأثير الدواء. قم بالاتصال بطبيك إذا أصبت بذلك.</p><p dir="RTL"><strong>يحتوي فوريك على الصوديوم </strong></p><p dir="RTL">تحتوي كل قارورة من فوريك على 217ز6 ملجم من الصوديوم لكل قارورة، ينبغي أن يؤخذ هذا في الإعتبار إن كنت تتبع حمية غذائية يتم فيها التحكم بنسبة الصوديوم بشكل دقيق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أحرص دوماً على تناول هذا الدواء تماماً كما أخبرك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكداً مما يجب عليك فعله.</p><p dir="RTL">سيقوم طبيبك بتحديد جرعتك اعتماداً على وزنك ونوع العدوى التي تعاني منها.</p><p dir="RTL">الجرعة الموصى بها للبالغين (بما في ذلك المرضى المسنين) هي كالآتي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">عبر الوريد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة للـ 24 ساعة الأولى (جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">6 ملجم/كلجم كل 12 ساعة للـ 24 ساعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة بعد الـ 24 ساعة (جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">4 ملجم/كلجم مرتين في اليوم</p></td></tr></tbody></table><p dir="RTL">تبعاً لاستجابتك للعلاج، قد يقلل طبيبك الجرعة اليومية إلى 3 ملجم/كلجم مرتين في اليوم</p><p dir="RTL">قد يقرر الطبيب خفض الجرعة إذا كنت مصاباً بتليف خفيف إلى متوسط بالكبد.</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين </strong></p><p dir="RTL">الجرعة الموصى بها للأطفال والمراهقين هي كالآتي:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p dir="RTL">عبر الوريد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة للـ 24 ساعة الأولى (جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">الأطفال من سن عامين وحتى أقل من 12 عاماً والمراهقون من سن 12 إلى 14 عاماً ويزنون اقل من 50 كجم</p></td><td style="vertical-align:top"><p dir="RTL">المراهقون من سن 12 إلى 14 عاماً ويزنون 50 كجم أو أكثر، وجميع المراهقين الأكبر من 14 عاماً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة للـ 24 ساعة الأولى (جرعة التحميل)</p></td><td style="vertical-align:top"><p dir="RTL">9 ملجم/كلجم كل 12 ساعة للـ 24 ساعة الأولى</p></td><td style="vertical-align:top"><p dir="RTL">6 ملجم/كلجم كل 12 ساعة للـ 24 ساعة الأولى</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجرعة بعد الـ 24 ساعة (جرعة المداومة)</p></td><td style="vertical-align:top"><p dir="RTL">8 ملجم/كلجم مرتين في يوم</p></td><td style="vertical-align:top"><p dir="RTL">4 ملجم/كلجم مرتين في يوم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يزيد طبيبك الجرعة اليومية أو يخفضها تبعاً لاستجابتك للعلاج</p><p dir="RTL">سيقوم صيدلي أو ممرض المستشفى الخاص بك بتحضير مسحوق فوريك المخصص لإعداد محلول للتسريب وتخفيفه إلى التركيز الصحيح. (يرجى الرجوع إلى نهاية هذه النشرة للاطلاع على المزيد من المعلومات).</p><p dir="RTL">سيتم اعطاؤك هذا الدواء من خلال التسريب عبر الوريد (في أحد الأوردة) بمعدل يبلغ 3 ملجم/كلجم في الساعة كحد أقصى على مدار فترة تتراوح بين ساعة و ثلاث ساعات.</p><p dir="RTL">إذا كنت تتناول، أنت أو طفلك، فوريك لمنع الإصابة بحالات العدوى الفطرية، يمكن أن يقوم طبيبك بإيقاف إعطائك فوريك إذا أصبت، أنت أو طفلك بالآثار الجانبية المرتبطة بالعلاج.</p><p dir="RTL"><strong>في حالة نسيانك تناول فوريك </strong></p><p dir="RTL">نظراً إلى أن هذا الدواء سوف يعطى لك تحت اشراف طبي دقيق، فمن غير المرجح أن يتم تفويت إحدى الجرعات. وبالرغم من ذلك، أخبر طبيبك أو الصيدلي إذا اعتقدت أنه قد تم نسيان إحدى الجرعات.</p><p dir="RTL"><strong>في حالة توقفك عن تناول فوريك </strong></p><p dir="RTL">سيستمر العلاج بفوريك طوال المدة الني ينصح بها طبيبك، ولكن مدة العلاج بمسحوق فوريك المخصص لإعداد محلول للتسريب ينبغي ألا تتجاوز 6 أشهر.</p><p dir="RTL">قد يحتاج المرضى الذين يعانون من ضعف في جهاز المناعة أو هؤلاء المصابون بحالات عدوى معالجتها إلى علاج طويل الأمد لمنع عودة العدوى مرة أخرى. يمكن أن يتم تحويلك من نظام العلاج بالتسريب عبر الوريد إلى العلاج بالأقراص بمجرد تحسن حالتك.</p><p dir="RTL">عندما يتم إيقاف العلاج بفوريك من قبل طبيبك، من المفترض ألا تصاب بأي آثار.</p><p>إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، غير أنها لا تصيب الجميع</p><p dir="RTL">إذا حدثت أي آثار جانبية، فسيكون أغلبها على الأرجح بسيطاً ومؤقتاً. ولكن قد يكون بعضها خطيراً ويحتاج إلى رعاية طبية.</p><p dir="RTL">الآثار الجانبية الخطيرة ـ توقف عن تناول فوريك واذهب إلى الطبيب على الفور</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان، تغير فحصوات الدم لوظائف الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">الآثار الجانبية الأخرى</p><p dir="RTL">شائعة جداً: قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في الرؤية (تغيرات في الرؤية بما في ذلك تغيم، تغيرات في الألوان المرئية، عدم التحمل غير الطبيعي للإدراك البصري للضوء عمى الألوان، اضطراب العين، رؤية هالة، العمى الليلي، اهتزاز الرؤية، رؤية أضواء ساطعة، رؤية ومضات من الضوء، انخفاض حدة الإبصار، السطوع البصري، فقدان جزء من مجال الرؤية المعتاد، رؤية ببقع أمام العينين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، القئ، الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات التفنس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد</p><p dir="RTL">شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب، التهاب اللثة القشعريرة، الضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أعداد بعض أنواع خلايا الدم الحمراء (أحياناً يكون مرتبطاً بالمناعة) و/ أو خلايا الدم البيضاء (مع حمى في بعض الأحيان)، بما في ذلك الانخفاض الشديد لهما، وانخفض أعداد خلايا تدعى الصفيحات الدموية، والتي تساعد الدم على التجلط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض سكر الدم، انخفاض بوتاسيوم الدم، انخفاض نسبة الصوديوم في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، الاكتئاب، التشوش، التهيج، عدم القدرة على النوم، الهلاوس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات، الرعاش أو حركات العضلات غير المتحكم فيها، الشعور بالوخز أو الأحاسيس غير الطبيعية في الجلد، زيادة توتر العضلات، النعاس، الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات نظم ضربات القلب بما في ذلك سرعة شديدة في نبضات القلب، أو بطء شديد في نبضات القلب، الإغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المنخفض، التهاب أحد الأوردة (الذي قد صاحبه تكون جلطة دموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة حادة في التنفس، ألم في الصدر، تورم الوجه (الفم، والشفتين، وحول العينين)، تراكم السوائل في الرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك، عسر الهضم، التهاب الشفتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان، والتهاب الكبد، وإصابة الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات طفح جلدي قد تؤدي بدورها إلى تقرحات شديدة وتقشر شديد للجلد، ويتميز بظهور مساحة مسطحة وحمراء من الجلد مغطاة بنتوءات مجمعة صغيرة، واحمرار الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى، ظهور دم البول، تغيرات في فحوصات وظائف الكلى</p><p dir="RTL">غير شائعة: قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه الإنفلونزا، تهيج الجهاز الهضمي، التهاب الجهاز الهضمي مما يؤدي إلى الإصابة بالإسهال المرتبط بالمضادات الحيوية، التهاب الأوعية الليمفاوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة الرفيعة التي تبطن الجدار الداخلي للبطن وتغطي أعضاء البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليفماوية (أحياناً ما يكون مؤلماً)، فشل وظيفي لنخاع الدم، زيادة اليوزينيات (الايزينوفيلز)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط وظيفة الغدة الكظرية، خمول نشاط الغدة الدرقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الدماغ غير طبيعية، الإصابة بأعراض مشابهة لمرض باكنسون، إصابة أحد الأعصاب مما يؤدي إلى الخدر ن أو الألم، أو الشعور بالوخز أو الحرقة في اليدين أو القدمين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في التوازن أو التناسق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الدماغ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية مزدوجة المعاناة من حالات خطيرة في العين بما في ذلك: الشعور بألم في العينين والجفون والتهابها، حركة غير طبيعية للعين، تلف العصب البصري مما يؤدي إلى خلل الرؤية، تورم القرص البصري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الحساسية للمس حاسة تذوق غير طبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في السمع، سماع طنين في الأذنين، الدوخة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بعض الأعضاء الداخلية، البنكرياس، والإثنى عشر، تورم اللسان والتهابه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الكبد، فشل الكبد، مرض المرارة،، حصوات المرارة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل، التهاب الأوردة تحت الجلد (الذي قد يكون مرتبطاً بتكون جلطة دموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى، وجود بروتينات في البول، تلف الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع معدل نبضات القلب بشكل زائد أو عدم انتظام نبضات القلب، يصاحبه أحيانا نبضات كهربائية شاذة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية برسم القلب (ECG)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع كوليسترول الدم، ارتفاع يوريا الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (تكون شديدة في بعض الأحيان)، بما في ذلك حالة جلدية مهددة للحياة تؤدي إلى ظهور تقرحات والتهابات مؤلمة في الجلد والأغشية المخاطية، خاصة في الفم، التهاب الجلد أو الشري أو حروق الشمس أو تفاعل جلدي شديد يعقب التعرض للضوء أو الشمس، احمرار الجلد وهياجه، تغير لون الجلد إلى الأحمر أو الأرجواني نتيجة لانخفاض تعداد الصفيحات الدومية، الإكزيما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات موضع التسريب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية أو استجابة مناعية مبالغ فيها نادرة قد تصيب ما يصل إلى شخص واحد ما بين كل 1000 شخص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغدة الدرقية مفرطة النشاط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور الوظائف الدماغية الذي يعتبر ضمن المضاعفات الخطيرة لمرض الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان معظم ألياف الصعب البصري، تغيم القرنية، حركة غير إرادية للعين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية فقاعية للضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب يقوم فيه الجهاز المناعي للجسم بمهاجمة أجزاء الجهاز العصبي الطرفي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في نظم ضربات القلب أو نظام التوصيل القلبي (تكون مهدد للحياة في بعض الأحيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية مهددة للحياة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نظام تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية جلدية (تكون شديدو في بعض الأحيان)، بما في ذلك تورم سيع لباطن الجلد والأنسجة تحت الجلد تحت الجلد والأنسجة المخاطية وتحت المخاطية، يقع ملتهبة مثيرة للحكة من الجلد الأحمر السميك، مصحوبة بقشور جلدية فضية اللون، تهيج الجلد والأغشية المخاطية، حالة جلدية مهددة جلدية مهددة للحياة تتسبب في فصل أجزاء كبيرة من البشرة وهي الطبقة الخارجية للجلد / هم طبقات الجلد السفلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع جلدية صغيرة جافة ذات قشور، وتكون سميكة في بعض الأحيان وبها &quot; سنون مدببة &quot; أو &quot; قرون &quot; الآثار الجانبية التي حدثت بمعدل تكرار غير معروف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النمش والبقع الملونة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار الجانبية المهمة الأخرى التي حدثت بمعدل تكرار غير معروف، ولكن ينبغي أن يتم إبلاغ طبيبك بها على الفور:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنسجة المحيطة بالعظم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء ذات قشور أو آفات جلدية حلقية الشكل قد تكون أحد أعراض مرض مناعي ذاتي يدعى لوباس ايريثمانوزس الجلدي ينبغي على طبيبك مراقبة وظائف الكبد والكلى عن طريق إجراء فحصوات الدم، ذلك لأن فوريك يعرف بتأثيره على الكبد والكلى. يرجى إخبار طبيبك إذا عانيت من أي آلام في المعدة أو إذا كان لبرازك درجة تماسك مختلفة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن حدوث حالات غصابة بسرطان الجلد في المرضى الذين تمت معالجتهم بواسطة فوريك لفترات طويلة من الزمن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدثت إصابات بحروق الشمس أو تفاعلات جلدية شديدة عقب التعرض للضوء أو الشمس بشكل أكثر تكراراً عند الأطفال. إذا أصبت أنت أو طفلك بأي من اضطرابات الجلد، فقد يحيلك طبيبك إلى طبيب جلد، الذي قد يقرر بدوره بعد الاستشارة أهمية تكرار زيارتك أنت أو طفلك له بشكل منتظم</p><p dir="RTL">وقد تمت أيضاً ملاحظة ارتفاع انزيمات الكبد بشكل أكثر تكراراً عند الأطفال.</p><p dir="RTL">إذا استمرت أي من هذه الآثار الجانبية أو أصبحت مزعجة، يرجى إخبار طبيبك.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يشمل هذا أي آثار جانبية محتملة وغير مدرجة في هذه النشرة. يمكنك أيضاً الإبلاغ عن الآثار الجانبية مباشرة عبر نظام الإبلاغ القومي بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء</p><p dir="RTL">للإبلاغ عن الآثار الجانبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على الهاتف: 00966112038222 تحويلة: 2340-2334-2354-2353-2356-2317</p><p dir="RTL">الهاتف المجاني: 8002490000</p><p dir="RTL">فاكس: +966112057662</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfds.gov.sa</p><p dir="RTL">الموقع الإلكتروني: www.sfda.gov.sa/mpc</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدا عن مرأى ومتناول الأطفال</p><p dir="RTL">لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على الملصق. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">صلاحية المستحضر 3 سنوات</p><p dir="RTL">يخزن في درجة حرارة أقل من 30 درجة مئوية</p><p dir="RTL">وبمجرد تحضير فوريك، يجب استخدامه على الفور، ولكن إذا لزم الأمر قد يتم تخزينها لمدة تصل إلى 24 ساعة في درجة حرارة تتراوح بين 2 - 8 درجة مئوية (في الثلاجة). يجب أولاً تخفيف فوريك المحضر بأحد محاليل التسريب المتوافقة قبل أن يتم تسريبه. (يرجى الرجوع إلى نهاية هذه النشرة للحصول على مزيد من المعلومات).</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو في المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات فوريك</strong></p><p dir="RTL">المادة الفعالة هي فوريكونازول.</p><p dir="RTL">المكوّن الآخر هو سلفوبوتيل إيثر بيتا سيكلوديكسترين الصوديوم.</p><p dir="RTL">كل قارورة تحتوي على 200 ملجم من فوريكونازول، ما يعادل حل 10 ملجم/مل عند يتم تحضيره وفقا لتوجيهات صيدلي أو ممرضة المستشفى (انظر المعلومات في نهاية هذه النشرة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتم تقديم فوريك في قارورة زجاجية ذات استخدام واحد في صورة مسحوق لإعداد محلول للتسريب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية</p><p dir="RTL">المدينة الصناعية، مدن بحائل، شارع رقم 32</p><p dir="RTL">حائل 55414، ص.ب 6979</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL"><strong>الشركة الصانعة</strong></p><p dir="RTL">شركة إلبين الدوائية</p><p dir="RTL">95 شارع ماراثونوس،GR-19009 &nbsp;بيكيرمي، أتيكا</p><p>اليونان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعةو هذة النشرة في 10/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VORIC 200 mg powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 200 mg of voriconazole.
After reconstitution each ml contains 10 mg of voriconazole.
Once reconstituted further dilution is required before administration.

Excipient with known effect: each vial contains 222 mg sodium. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.
White to off-white freeze-dried powder or cake

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VORIC is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:</p><p>&nbsp;</p><p>Treatment of invasive aspergillosis.</p><p>&nbsp;</p><p>Treatment of candidaemia in non-neutropenic patients.</p><p>&nbsp;</p><p>Treatment of fluconazole-resistant serious invasive <em>Candida </em>infections (including <em>C. krusei</em>). Treatment of serious fungal infections caused by <em>Scedosporium </em>spp. and <em>Fusarium </em>spp.</p><p>VORIC should be administered primarily to patients with progressive, possibly life-threatening infections.</p><p>&nbsp;</p><p>Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4).</p><p>&nbsp;</p><p>It is recommended that VORIC is administered at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.</p><p>&nbsp;</p><p><u>Treatment</u></p><p><em>Adults</em></p><p>Therapy must be initiated with the specified loading dose regimen of intravenous voriconazole to achieve plasma concentrations on Day 1 that are close to steady state.</p><p>&nbsp;</p><p>Detailed information on dosage recommendations is provided in the following table:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Intravenous</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading dose regimen (first 24 hours)</strong></p></td><td style="vertical-align:top"><p>6 mg/kg every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance dose (after first 24 hours)</strong></p></td><td style="vertical-align:top"><p>4 mg/kg twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Duration of treatment</u></em></p><p>Treatment duration should be as short as possible depending on the patient&rsquo;s clinical and mycological response. Long term exposure to voriconazole greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Adults)</u></em></p><p>If patient is unable to tolerate intravenous treatment at 4 mg/kg twice daily, reduce the dose to 3 mg/kg twice daily.</p><p>&nbsp;</p><p>In case of use as prophylaxis, refer below.</p><p>&nbsp;</p><p><em>Children (2 to &lt;12 years) and young adolescents with low body weight (12 to 14 years and &lt;50 kg) </em>Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.</p><p>&nbsp;</p><p>The recommended dosing regimen is as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Intravenous</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Loading Dose Regimen (first 24 hours)</strong></p></td><td style="vertical-align:top"><p>9 mg/kg every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance Dose (after first 24 hours)</strong></p></td><td style="vertical-align:top"><p>8 mg/kg twice daily</p></td></tr></tbody></table><p>Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescents aged 12 to &lt;17 years.</p><p>&nbsp;</p><p>It is recommended to initiate the therapy with intravenous regimen. It should be noted that an 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p><em>All other adolescents (12 to 14 years and &ge;50 kg; 15 to 17 years regardless of body weight) </em>Voriconazole should be dosed as adults.</p><p>&nbsp;</p><p><em><u>Dosage adjustment (Children [2 to &lt;12 years] and young adolescents with low body weight [12 to 14</u> <u>years and &lt;50 kg])</u></em></p><p>If patient response to treatment is inadequate, the intravenous dose may be increased by 1 mg/kg steps. If patient is unable to tolerate treatment, reduce the intravenous dose by 1 mg/kg steps.</p><p>&nbsp;</p><p>Use in paediatric patients aged 2 to &lt;12 years with hepatic or renal insufficiency has not been studied (see sections 4.8 and 5.2).</p><p>&nbsp;</p><p><u>Prophylaxis in Adults and Children</u></p><p>Prophylaxis should be initiated on the day of transplant and may be administered for up to 100 days. Prophylaxis should be as short as possible depending on the risk for developing invasive fungal infection (IFI) as defined by neutropenia or immunosuppression. It may only be continued up to 180 days after transplantation in case of continuing immunosuppression or graft versus host disease (GvHD) (see section 5.1).</p><p>&nbsp;</p><p><em>Dosage</em></p><p>The recommended dosing regimen for prophylaxis is the same as for treatment in the respective age groups. Please refer to the treatment tables above.</p><p>&nbsp;</p><p><em>Duration of prophylaxis</em></p><p>The safety and efficacy of voriconazole use for longer than 180 days has not been adequately studied in clinical trials.</p><p>&nbsp;</p><p>Use of voriconazole in prophylaxis for greater than 180 days (6 months) requires careful assessment of the benefit-risk balance (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><u>The following instructions apply to both Treatment and Prophylaxis</u></p><p>&nbsp;</p><p><em>Dosage adjustment</em></p><p>For prophylaxis use, dose adjustments are not recommended in the case of lack of efficacy or treatment- related adverse events. In the case of treatment-related adverse events, discontinuation of voriconazole and use of alternative antifungal agents must be considered (see section 4.4 and 4.8)</p><p>&nbsp;</p><p><em><u>Dosage adjustments in case of co-administration</u></em></p><p>Rifabutin or phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg intravenously twice daily, see sections 4.4 and 4.5.</p><p>&nbsp;</p><p>Efavirenz may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 400 mg every 12 hours and the efavirenz dose is reduced by 50%, i.e. to 300 mg once daily. When treatment with voriconazole is stopped, the initial dosage of efavirenz should be restored (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>In patients with moderate to severe renal dysfunction (creatinine clearance &lt; 50 ml/min), accumulation of the intravenous vehicle, Betadex Sulfobutyl Ether Sodium, occurs. Oral voriconazole should be administered to these patients, unless an assessment of the risk benefit to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients and, if increases occur, consideration should be given to changing to oral voriconazole therapy (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. A 4-hour haemodialysis session does not remove a sufficient amount of voriconazole to warrant dose adjustment.</p><p>&nbsp;</p><p>The intravenous vehicle, Betadex Sulfobutyl Ether Sodium, is haemodialysed with a clearance of 55 ml/min.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>It is recommended that the standard loading dose regimens be used but that the maintenance dose be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B) receiving voriconazole (see section 5.2).</p><p>&nbsp;</p><p>Voriconazole has not been studied in patients with severe chronic hepatic cirrhosis (Child-Pugh C).</p><p>&nbsp;</p><p>There is limited data on the safety of voriconazole in patients with abnormal liver function tests (aspartate transaminase [AST], alanine transaminase [ALT], alkaline phosphatase [ALP], or total bilirubin &gt;5 times the upper limit of normal).</p><p>&nbsp;</p><p>Voriconazole has been associated with elevations in liver function tests and clinical signs of liver damage, such as jaundice, and must only be used in patients with severe hepatic impairment if the benefit outweighs the potential risk. Patients with severe hepatic impairment must be carefully monitored for drug toxicity (see section 4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of voriconazole in children below 2 years has not been established. Currently available data are described in sections 4.8 and 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>VORIC requires reconstitution and dilution (see section 6.6) prior to administration as an intravenous infusion. Not for bolus injection.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Coadministration with CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozide or quinidine since increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences of torsades de pointes (see section 4.5).

Coadministration with rifampicin, carbamazepine and phenobarbital since these medicinal products are likely to decrease plasma voriconazole concentrations significantly (see section 4.5).

Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg once daily or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations (see section 4.5, for lower doses see section 4.4).

Coadministration with high-dose ritonavir (400 mg and above twice daily) because ritonavir significantly decreases plasma voriconazole concentrations in healthy subjects at this dose (see section 4.5, for lower doses see section 4.4).

Coadministration with ergot alkaloids (ergotamine, dihydroergotamine), which are CYP3A4 substrates, since increased plasma concentrations of these medicinal products can lead to ergotism (see section 4.5).

Coadministration with sirolimus since voriconazole is likely to increase plasma concentrations of sirolimus significantly (see section 4.5).

Coadministration with St. John’s Wort (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>Caution should be used in prescribing VORIC to patients with hypersensitivity to other azoles (see also section 4.8).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>The duration of treatment with the intravenous formulation should be no longer than 6 months (see section 5.3).</p><p>&nbsp;</p><p><u>Cardiovascular</u></p><p>Voriconazole has been associated with QTc interval prolongation. There have been rare cases of torsades de pointes in patients taking voriconazole who had risk factors, such as history of cardiotoxic chemotherapy, cardiomyopathy, hypokalaemia and concomitant medicinal products that may have been contributory. Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, such as:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congenital or acquired QTc-prolongation.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiomyopathy, in particular when heart failure is present.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinus bradycardia.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Existing symptomatic arrhythmias.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Concomitant medicinal product that is known to prolong QTc interval. Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2). A study has been conducted in healthy volunteers which examined the effect on QTc interval of single doses of voriconazole up to 4 times the usual daily dose. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500 msec (see section 5.1).</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Infusion-related reactions, predominantly flushing and nausea, have been observed during administration of the intravenous formulation of voriconazole. Depending on the severity of symptoms, consideration should be given to stopping treatment (see section 4.8).</p><p>&nbsp;</p><p><u>Hepatic toxicity</u></p><p>In clinical trials, there have been cases of serious hepatic reactions during treatment with voriconazole (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities). Instances of hepatic reactions were noted to occur primarily in patients with serious underlying medical conditions (predominantly haematological malignancy). Transient hepatic reactions, including hepatitis and jaundice, have occurred among patients with no other identifiable risk factors. Liver dysfunction has usually been reversible on discontinuation of therapy (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of hepatic function</u></p><p>Patients receiving voriconazole must be carefully monitored for hepatic toxicity. Clinical management should include laboratory evaluation of hepatic function (specifically AST and ALT) at the initiation of treatment with voriconazole and at least weekly for the first month of treatment. Treatment duration should be as short as possible; however, if based on the benefit-risk assessment the treatment is continued (see section 4.2), monitoring frequency can be reduced to monthly if there are no changes in the liver function tests.</p><p>&nbsp;</p><p>If the liver function tests become markedly elevated, voriconazole should be discontinued, unless the medical judgment of the risk-benefit of the treatment for the patient justifies continued use.</p><p>Monitoring of hepatic function should be carried out in both children and adults. <u>Visual adverse reactions</u></p><p>There have been reports of prolonged visual adverse reactions, including blurred vision, optic neuritis and</p><p>papilloedema (see section 4.8).</p><p>&nbsp;</p><p><u>Renal adverse reactions</u></p><p>Acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medicinal products and have concurrent conditions that may result in decreased renal function (see section 4.8).</p><p>&nbsp;</p><p><u>Monitoring of renal function</u></p><p>Patients should be monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.</p><p>&nbsp;</p><p><u>Monitoring of pancreatic function</u></p><p>Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during voriconazole treatment. Monitoring of serum amylase or lipase may be considered in this clinical situation.</p><p>&nbsp;</p><p><u>Dermatological adverse reactions</u></p><p>Patients have developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome, during treatment with voriconazole. If a patient develops a rash he should be monitored closely and voriconazole discontinued if lesions progress.</p><p>&nbsp;</p><p>In addition voriconazole has been associated with phototoxicity, including reactions such as ephelides, lentigo, actinic keratosis and pseudoporphyria. It is recommended that all patients, including children, avoid exposure to direct sunlight during voriconazole treatment and use measures such as protective clothing and sunscreen with high sun protection factor (SPF).</p><p>&nbsp;</p><p><u>Long-term treatment</u></p><p>Long term exposure (treatment or prophylaxis) greater than 180 days (6 months) requires careful assessment of the benefit-risk balance and physicians should therefore consider the need to limit the exposure to voriconazole (see sections 4.2 and 5.1). The following severe adverse events have been reported in relation with long-term voriconazole treatment:</p><p>&nbsp;</p><p><u>Squamous cell carcinoma of the skin (SCC)</u> has been reported in patients, some of whom have reported prior phototoxic reactions. If phototoxic reactions occur, multidisciplinary advice should be sought and the patient should be referred to a dermatologist. Voriconazole discontinuation and use of alternative antifungal agents should be considered. Dermatologic evaluation should be performed on a systematic and regular basis, whenever voriconazole is continued despite the occurrence of phototoxicity-related lesions, to allow early detection and management of premalignant lesions. Voriconazole should be discontinued if premalignant skin lesions or squamous cell carcinoma are identified.</p><p>&nbsp;</p><p><u>Non-infectious periostitis with elevated fluoride and alkaline phosphatase levels </u>has been reported in transplant patients. If a patient develops skeletal pain and radiologic findings compatible with periostitis voriconazole discontinuation should be considered after multidisciplinary advice.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Safety and effectiveness in paediatric subjects below the age of two years has not been established (see sections 4.8 and 5.1). Voriconazole is indicated for paediatric patients aged two years or older. A higher frequency of liver enzyme elevations was observed in the paediatric population (see section 4.8). Hepatic function should be monitored in both children and adults. Oral bioavailability may be limited in paediatric patients aged 2 to &lt;12 years with malabsorption and very low body weight for age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>The frequency of phototoxicity reactions is higher in the paediatric population. As an evolution towards SCC has been reported, stringent measures for the photoprotection are warranted in this population of patients. In children experiencing photoaging injuries such as lentigines or ephelides, sun avoidance and dermatologic follow-up are recommended even after treatment discontinuation.</p><p>&nbsp;</p><p><u>Prophylaxis</u></p><p>In case of treatment-related adverse events (hepatotoxicity, severe skin reactions including phototoxicity and SCC, severe or prolonged visual disorders and periostitis), discontinuation of voriconazole and use of alternative antifungal agents must be considered.</p><p>&nbsp;</p><p><u>Phenytoin (CYP2C9 substrate and potent CYP450 inducer)</u></p><p>Careful monitoring of phenytoin levels is recommended when phenytoin is coadministered with voriconazole. Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Efavirenz (CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>When voriconazole is coadministered with efavirenz the dose of voriconazole should be increased to 400 mg every 12 hours and the dose of efavirenz should be decreased to 300 mg every 24 hours (see sections 4.2, 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Rifabutin (Potent CYP450 inducer)</u></p><p>Careful monitoring of full blood counts and adverse reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole. Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk (see section 4.5).</p><p>&nbsp;</p><p><u>Ritonavir (potent CYP450 inducer; CYP3A4 inhibitor and substrate)</u></p><p>Coadministration of voriconazole and low-dose ritonavir (100 mg twice daily) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><u>Everolimus (CYP3A4 substrate, P-gp substrate)</u></p><p>Coadministration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations. Currently there are insufficient data to allow dosing recommendations in this situation (see section 4.5).</p><p>&nbsp;</p><p><u>Methadone (CYP3A4 substrate)</u></p><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended when coadministered with voriconazole since methadone levels increased following coadministration of voriconazole. Dose reduction of methadone may be needed (see section 4.5).</p><p>&nbsp;</p><p><u>Short-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered when coadministered with voriconazole (see section 4.5). As the half-life of alfentanil is prolonged in a 4-fold manner when alfentanil is coadministered with voriconazole, and in an independent published study concomitant use of voriconazole with fentanyl resulted in an increase in the mean AUC0-&infin; of fentanyl, frequent monitoring for opiate- associated adverse reactions (including a longer respiratory monitoring period) may be necessary<strong><em>.</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><u>Long-acting opiates (CYP3A4 substrate)</u></p><p>Reduction in the dose of oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered when coadministered with voriconazole. Frequent monitoring for opiate- associated adverse reactions may be necessary (see section 4.5).</p><p>&nbsp;</p><p><u>Fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor)</u></p><p>Coadministration of oral voriconazole and oral fluconazole resulted in a significant increase in Cmax and AUC&tau; of voriconazole in healthy subjects. The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole- associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains 222mg of sodium per vial. To be taken under consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole is metabolised by, and inhibits the activity of, cytochrome P450 isoenzymes, CYP2C19, CYP2C9, and CYP3A4. Inhibitors or inducers of these isoenzymes may increase or decrease voriconazole plasma concentrations, respectively, and there is potential for voriconazole to increase the plasma concentrations of substances metabolised by these CYP450 isoenzymes.</p><p>&nbsp;</p><p>Unless otherwise specified, drug interaction studies have been performed in healthy adult male subjects using multiple dosing to steady state with oral voriconazole at 200 mg twice daily (BID). These results are relevant to other populations and routes of administration.</p><p>&nbsp;</p><p>Voriconazole should be administered with caution in patients with concomitant medication that is known to prolong QTc interval. When there is also a potential for voriconazole to increase the plasma concentrations of substances metabolised by CYP3A4 isoenzymes (certain antihistamines, quinidine, cisapride, pimozide), coadministration is contraindicated (see below and section 4.3).</p><p>&nbsp;</p><p><u>Interaction table</u></p><p>Interactions between voriconazole and other medicinal products are listed in the table below (once daily as &ldquo;QD&rdquo;, twice daily as &ldquo;BID&rdquo;, three times daily as &ldquo;TID&rdquo; and not determined as &ldquo;ND&rdquo;). The direction of the arrow for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (&harr;), below (&darr;) or above (&uarr;) the 80-125% range. The asterisk (*) indicates a two-way interaction. AUC&tau;, AUCt and AUC0-&infin; represent area under the curve over a dosing interval, from time zero to the time with detectable measurement and from time zero to infinity, respectively.</p><p>&nbsp;</p><p>The interactions in the table are presented in the following order: contraindications, those requiring dose adjustment and careful clinical and/or biological monitoring, and finally those that have no significant pharmacokinetic interaction but may be of clinical interest in this therapeutic field.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning</strong></p><p><strong>coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Astemizole, cisapride, pimozide, quinidine and terfenadine</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, increased plasma concentrations of these medicinal products can lead to QTc prolongation and rare occurrences</p><p>of torsades de pointes.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine and long-acting barbiturates (e.g., phenobarbital, mephobarbital)</p><p><em>[potent CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Although not studied, carbamazepine and long-acting barbiturates are likely to significantly decrease plasma</p><p>voriconazole concentrations.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz (a non-nucleoside reverse transcriptase inhibitor) <em>[CYP450 inducer; CYP3A4 inhibitor and substrate]</em></p><p>&nbsp;</p><p>Efavirenz&nbsp;&nbsp;&nbsp;&nbsp; 400&nbsp;&nbsp;&nbsp;&nbsp; mg&nbsp;&nbsp;&nbsp;&nbsp; QD, coadministered with</p><p>voriconazole 200 mg BID<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz 300 mg QD, coadministered with voriconazole 400 mg BID<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Efavirenz Cmax 38% Efavirenz AUC44% Voriconazole Cmax 61% Voriconazole AUC77%</p><p>&nbsp;</p><p>&nbsp;</p><p>Compared to efavirenz 600 mg QD, Efavirenz Cmax &harr;</p><p>Efavirenz AUC17%</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 23% Voriconazole AUC7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Use of standard doses of voriconazole with efavirenz doses of 400 mg QD or higher is <strong>contraindicated </strong>(see section 4.3).</p><p>&nbsp;</p><p>Voriconazole may be coadministered with efavirenz if the voriconazole maintenance dose is increased to 400 mg BID and the efavirenz dose is decreased to 300 mg QD. When voriconazole treatment is stopped, the initial dose of efavirenz should be restored (see section 4.2 and 4.4).</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Ergot alkaloids (e.g., ergotamine and dihydroergotamine)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of ergot alkaloids</p><p>and lead to ergotism.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p><em>[potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300 mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 350 mg BID)<sup>*</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 400 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax 69% Voriconazole AUC78%</p><p>&nbsp;</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4%&nbsp;Voriconazole AUC32%</p><p>&nbsp;</p><p>Rifabutin Cmax 195% Rifabutin AUC331%</p><p>Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 104% Voriconazole AUC87%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of voriconazole and rifabutin should be avoided unless the benefit outweighs the risk. The maintenance dose of voriconazole may be increased to 5 mg/kg intravenously BID or from 200 mg to 350 mg orally BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood counts and adverse</p><p>reactions to rifabutin (e.g., uveitis) is recommended when rifabutin is coadministered with voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin (600 mg QD)</p><p><em>[potent CYP450 inducer]</em></p></td><td style="vertical-align:top"><p>Voriconazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 93%</p><p>Voriconazole AUC96%</p></td><td style="vertical-align:top"><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir (protease inhibitor) <em>[potent CYP450 inducer; CYP3A4 inhibitor and substrate]</em></p><p>&nbsp;</p><p>High dose (400 mg BID)</p><p>&nbsp;</p><p>&nbsp;</p><p>Low dose (100 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Ritonavir&nbsp;Cmax and&nbsp;AUC&harr;&nbsp;Voriconazole Cmax 66% Voriconazole AUC82%</p><p>&nbsp;</p><p>&nbsp;</p><p>Ritonavir Cmax 25% Ritonavir AUC13% Voriconazole Cmax 24% Voriconazole AUC39%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and high doses of ritonavir (400 mg and above BID) is <strong>contraindicated </strong>(see section 4.3).</p><p>&nbsp;</p><p>Coadministration of voriconazole and low-dose ritonavir (100 mg BID) should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.</p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s Wort <em>[CYP450 inducer; P- gp inducer]</em></p><p>300 mg TID (coadministered with voriconazole 400 mg</p><p>single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Voriconazole AUC0-59%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong>Contraindicated </strong>(see section 4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Everolimus</p><p><em>[CYP3A4 substrate, P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to significantly increase the plasma concentrations of everolimus.</p></td><td style="vertical-align:top"><p>Coadministration of voriconazole with everolimus is not recommended because voriconazole is expected to significantly increase everolimus concentrations (see</p><p>section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole (200 mg QD)</p><p><em>[CYP2C9, CYP2C19 and</em></p><p><em>CYP3A4 inhibitor]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax 57% Voriconazole AUC79%&nbsp;Fluconazole Cmax ND Fluconazole AUC ND</p></td><td style="vertical-align:top"><p>The reduced dose and/or frequency of voriconazole and fluconazole that would eliminate this effect have not been established. Monitoring for voriconazole-associated adverse reactions is recommended if voriconazole is used sequentially after</p><p>fluconazole.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p><p><em>[CYP2C9 substrate and potent CYP450 inducer]</em></p><p>&nbsp;</p><p>300 mg QD</p><p>&nbsp;</p><p>&nbsp;</p><p>300 mg QD (coadministered with voriconazole 400 mg BID)<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax 49% Voriconazole AUC69%</p><p>&nbsp;</p><p>&nbsp;</p><p>Phenytoin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 67%&nbsp;Phenytoin AUC81% Compared to voriconazole 200 mg BID,</p><p>Voriconazole Cmax 34% Voriconazole AUC39%</p></td><td style="vertical-align:top"><p>Concomitant use of voriconazole and phenytoin should be avoided unless the benefit outweighs the risk. Careful monitoring of phenytoin plasma levels is recommended.</p><p>&nbsp;</p><p>Phenytoin may be coadministered with voriconazole if the maintenance dose of voriconazole is increased to 5 mg/kg IV BID or from 200 mg to 400 mg oral BID</p><p>(100 mg to 200 mg oral BID in patients less than 40 kg) (see section 4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Anticoagulants</p><p>&nbsp;</p><p>Warfarin (30 mg single dose, co- administered with 300 mg BID voriconazole)</p><p><em>[CYP2C9 substrate]</em></p><p>&nbsp;</p><p>Other oral coumarins (e.g., phenprocoumon, acenocoumarol) <em>[CYP2C9 and CYP3A4</em></p><p><em>substrates]</em></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Maximum increase in prothrombin time was approximately 2-fold.</p><p>&nbsp;</p><p>&nbsp;</p><p>Although not studied, voriconazole may increase the plasma concentrations of coumarins that may cause an increase in prothrombin time.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Close monitoring of prothrombin time or other suitable anticoagulation tests is recommended, and the dose of anticoagulants should be adjusted accordingly.</p></td></tr><tr><td style="vertical-align:top"><p>Benzodiazepines (e.g., midazolam, triazolam, alprazolam)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although&nbsp;&nbsp; not&nbsp;&nbsp; studied&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinically, voriconazole is likely to increase the plasma concentrations of benzodiazepines that are metabolised by CYP3A4 and lead to a prolonged sedative effect.</p></td><td style="vertical-align:top"><p>Dose reduction of benzodiazepines should be considered.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Sirolimus (2 mg single dose)</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin (in stable renal transplant recipients receiving chronic ciclosporin therapy)</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus (0.1 mg/kg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Sirolimus Cmax 6.6-fold Sirolimus AUC0-11-fold</p><p>&nbsp;</p><p>&nbsp;</p><p>Ciclosporin Cmax 13% Ciclosporin AUC70%</p><p>&nbsp;</p><p>&nbsp;</p><p>Tacrolimus Cmax 117%&nbsp;Tacrolimus&nbsp;AUCt 221%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Coadministration of voriconazole and sirolimus is <strong>contraindicated </strong>(see section 4.3).</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on ciclosporin it is recommended that the ciclosporin dose be halved and ciclosporin level carefully monitored. Increased ciclosporin levels have been associated with nephrotoxicity. <u>When voriconazole is</u> <u>discontinued,ciclosporin levels</u> <u>must be carefully</u> <u>monitored</u> <u>and the dose</u> <u>increased as</u> <u>necessary</u>.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already on tacrolimus, it is recommended that the tacrolimus dose be reduced to a third of the original dose and tacrolimus level carefully monitored. Increased tacrolimus levels have been associated with nephrotoxicity.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>When</u> <u>voriconazole is discontinued,</u> <u>tacrolimus levels must be</u> <u>carefully monitored and the</u></p><p><u>dose increased as necessary</u>.</p></td></tr><tr><td style="vertical-align:top"><p>Long-Acting Opiates</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Oxycodone (10 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>In an independent published study, Oxycodone Cmax 1.7-fold Oxycodone AUC0-3.6-fold</p></td><td style="vertical-align:top"><p>Dose reduction in oxycodone and other long-acting opiates metabolized by CYP3A4 (e.g., hydrocodone) should be considered. Frequent monitoring for opiate- associated adverse reactions</p><p>may be necessary.</p></td></tr><tr><td style="vertical-align:top"><p>Methadone (32-100 mg QD)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>R-methadone&nbsp;(active)&nbsp;Cmax 31%&nbsp;R-methadone (active) AUC47%</p><p>S-methadone Cmax 65%</p><p>S-methadone AUC103%</p></td><td style="vertical-align:top"><p>Frequent monitoring for adverse reactions and toxicity related to methadone, including QTc prolongation, is recommended. Dose reduction</p><p>of methadone may be needed.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) <em>[CYP2C9 substrates]</em></p><p>&nbsp;</p><p>Ibuprofen (400 mg single dose)</p><p>&nbsp;</p><p>Diclofenac (50 mg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>S-Ibuprofen Cmax 20%</p><p>S-Ibuprofen AUC0-100%</p><p>&nbsp;</p><p>Diclofenac Cmax 114% Diclofenac AUC0-78%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Frequent monitoring for adverse reactions and toxicity related to NSAIDs is recommended. Dose reduction of NSAIDs may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Omeprazole (40 mg QD)<sup>*</sup> <em>[CYP2C19 inhibitor; CYP2C19 and CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Omeprazole Cmax 116% Omeprazole AUC280%&nbsp;Voriconazole Cmax 15% Voriconazole AUC41%</p><p>&nbsp;</p><p>Other proton pump inhibitors that are CYP2C19 substrates may also be inhibited by voriconazole and may result in increased plasma concentrations of these medicinal</p><p>products.</p></td><td style="vertical-align:top"><p>No dose adjustment of voriconazole is recommended.</p><p>&nbsp;</p><p>When initiating voriconazole in patients already receiving omeprazole doses of 40 mg or above, it is recommended that the omeprazole dose be halved.</p></td></tr><tr><td style="vertical-align:top"><p>Oral Contraceptives<sup>*</sup> <em>[CYP3A4 substrate; CYP2C19 inhibitor]</em></p><p>Norethisterone/ethinylestradiol (1 mg/0.035 mg QD)</p></td><td style="vertical-align:top"><p>Ethinylestradiol Cmax 36% Ethinylestradiol AUC61%&nbsp;Norethisterone Cmax 15% Norethisterone AUC53%</p><p>Voriconazole Cmax 14% Voriconazole AUC46%</p></td><td style="vertical-align:top"><p>Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Short-acting Opiates</p><p><em>[CYP3A4 substrates]</em></p><p>&nbsp;</p><p>Alfentanil (20 &mu;g/kg single dose, with concomitant naloxone)</p><p>&nbsp;</p><p>Fentanyl (5 g/kg single dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>In an independent published study, Alfentanil AUC0-6-fold</p><p>&nbsp;</p><p>In an independent published study, Fentanyl&nbsp;AUC0-1.34-fold</p></td><td style="vertical-align:top"><p>Dose reduction of alfentanil, fentanyl and other short-acting opiates similar in structure to alfentanil and metabolised by CYP3A4 (e.g., sufentanil) should be considered.</p><p>Extended and frequent monitoring for respiratory depression and other opiate- associated adverse reactions is</p><p>recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Statins (e.g., lovastatin)</p><p><em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied clinically, voriconazole is likely to increase the plasma concentrations of statins that are metabolised by CYP3A4 and</p><p>could lead to rhabdomyolysis.</p></td><td style="vertical-align:top"><p>Dose reduction of statins should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>Sulfonylureas (e.g., tolbutamide, glipizide, glyburide)</p><p><em>[CYP2C9 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of sulfonylureas and</p><p>cause hypoglycaemia.</p></td><td style="vertical-align:top"><p>Careful monitoring of blood glucose is recommended.</p><p>Dose reduction of</p><p>sulfonylureas</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Vinca Alkaloids (e.g., vincristine and vinblastine) <em>[CYP3A4 substrates]</em></p></td><td style="vertical-align:top"><p>Although not studied, voriconazole is likely to increase the plasma concentrations of vinca alkaloids</p><p>and lead to neurotoxicity.</p></td><td style="vertical-align:top"><p>shoulDose dreductio be considered.n of vinca alkaloids should be</p><p>considered.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product</strong></p><p><strong><em>[Mechanism of interaction]</em></strong></p></td><td style="vertical-align:top"><p><strong>Interaction</strong></p><p><strong>Geometric mean changes (%)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations</strong></p><p><strong>concerning coadministration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other HIV Protease Inhibitors (e.g., saquinavir, amprenavir and nelfinavir)<sup>*</sup></p><p><em>[CYP3A4 substrates and inhibitors]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro </em>studies show that voriconazole may inhibit the metabolism of HIV protease inhibitors and the metabolism of voriconazole may also be inhibited by HIV protease</p><p>inhibitors.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Other Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) (e.g., delavirdine, nevirapine)<sup>*</sup></p><p><em>[CYP3A4 substrates, inhibitors or CYP450 inducers]</em></p></td><td style="vertical-align:top"><p>Not studied clinically. <em>In vitro </em>studies show that the metabolism of voriconazole may be inhibited by NNRTIs and voriconazole may inhibit the metabolism of NNRTIs. The findings of the effect of efavirenz on voriconazole suggest that the metabolism of voriconazole</p><p>may be induced by an NNRTI.</p></td><td style="vertical-align:top"><p>Careful monitoring for any occurrence of drug toxicity and/or lack of efficacy, and dose adjustment may be needed.</p></td></tr><tr><td style="vertical-align:top"><p>Cimetidine (400 mg BID) <em>[non- specific CYP450 inhibitor and</em></p><p><em>increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cmax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18%&nbsp;Voriconazole AUC23%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Digoxin (0.25 mg QD) <em>[P-gp substrate]</em></p></td><td style="vertical-align:top"><p>Digoxin Cmax &harr;</p><p>Digoxin AUC&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir (800 mg TID) <em>[CYP3A4 inhibitor and substrate]</em></p></td><td style="vertical-align:top"><p>Indinavir Cmax &harr; Indinavir AUC&harr;&nbsp;Voriconazole Cmax &harr;</p><p>Voriconazole AUC&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Macrolide antibiotics</p><p>&nbsp;</p><p>Erythromycin&nbsp;&nbsp;&nbsp; (1&nbsp;&nbsp;&nbsp;&nbsp; g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BID)</p><p><em>[CYP3A4 inhibitor]</em></p><p>&nbsp;</p><p>Azithromycin (500 mg QD)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Voriconazole Cmax and AUC&harr;</p><p>&nbsp;</p><p>Voriconazole Cmax and AUC&harr;</p><p>&nbsp;</p><p>The effect of voriconazole on either erythromycin or azithromycin is unknown.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Mycophenolic acid (1 g single dose)</p><p><em>[UDP-glucuronyl transferase substrate]</em></p></td><td style="vertical-align:top"><p>Mycophenolic acid Cmax &harr;</p><p>Mycophenolic acid AUCt &harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Prednisolone (60 mg single dose)</p><p><em>[CYP3A4 substrate]</em></p></td><td style="vertical-align:top"><p>Prednisolone Cmax 11% Prednisolone AUC0-34%</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr><tr><td style="vertical-align:top"><p>Ranitidine (150 mg BID)</p><p><em>[increases gastric pH]</em></p></td><td style="vertical-align:top"><p>Voriconazole Cmax and AUC&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data on the use of voriconazole in pregnant women available.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>Voriconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Women of child-bearing potential</u></p><p>Women of child-bearing potential must always use effective contraception during treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>The excretion of voriconazole into breast milk has not been investigated. Breast-feeding must be stopped on initiation of treatment with Voriconazole.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In an animal study, no impairment of fertility was demonstrated in male and female rats (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voriconazole has moderate influence on the ability to drive and use machines. It may cause transient and reversible changes to vision, including blurring, altered/enhanced visual perception and/or photophobia. Patients must avoid potentially hazardous tasks, such as driving or operating machinery while experiencing these symptoms.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The safety profile of voriconazole in adults is based on an integrated safety database of more than 2,000 subjects (including 1,603 adult patients in therapeutic trials) and an additional 270 adults in prophylaxis trials. This represents a heterogeneous population, containing patients with haematological malignancy, HIV-infected patients with oesophageal candidiasis and refractory fungal infections, non-neutropenic patients with candidaemia or aspergillosis and healthy volunteers.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions were visual impairment, pyrexia, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, liver function test abnormal, respiratory distress and abdominal pain.</p><p>&nbsp;</p><p>The severity of the adverse reactions was generally mild to moderate. No clinically significant differences were seen when the safety data were analysed by age, race, or gender.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>In the table below, since the majority of the studies were of an open nature, all causality adverse reactions and their frequency categories in 1,873 adults from pooled therapeutic (1,603) and prophylaxis</p><p>(270) studies, by system organ class, are listed.</p><p>&nbsp;</p><p>Frequency categories are expressed as: Very common (1/10); Common (1/100 to 1/10); Uncommon (1/1,000 to 1/100); Rare (1/10,000 to 1/1,000); Very rare (1/10,000); Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Undesirable effects reported in subjects receiving voriconazole:</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/1,000 to &lt;</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/10,000 to &lt;</strong></p></td><td style="vertical-align:top"><p><strong>not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>1/100</strong></p></td><td style="vertical-align:top"><p><strong>1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>(cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>pseudomembranous colitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and</p><p>polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>squamous cell carcinoma*</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>1</sup>, pancytopenia, thrombocytopenia<sup>2</sup>, leukopenia,</p><p>anaemia</p></td><td style="vertical-align:top"><p>bone marrow failure, lymphadenopathy, eosinophilia</p></td><td style="vertical-align:top"><p>disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune</p><p>system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactoid reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>adrenal insufficiency,</p><p>hypothyroidism</p></td><td style="vertical-align:top"><p>hyperthyroidism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition</p><p>disorders</p></td><td style="vertical-align:top"><p>oedema peripheral</p></td><td style="vertical-align:top"><p>hypoglycaemia, hypokalaemia,</p><p>hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>depression, hallucination, anxiety, insomnia, agitation,</p><p>confusional state</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>convulsion, syncope, tremor, hypertonia<sup>3</sup>, paraesthesia, somnolence, dizziness</p></td><td style="vertical-align:top"><p>brain oedema, encephalopathy<sup>4</sup>, extrapyramidal disorder<sup>5</sup>, neuropathy peripheral, ataxia, hypoaesthesia,</p><p>dysgeusia</p></td><td style="vertical-align:top"><p>hepatic encephalopathy, Guillain-Barre syndrome, nystagmus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>visual impairment<sup>6</sup></p></td><td style="vertical-align:top"><p>retinal haemorrhage</p></td><td style="vertical-align:top"><p>optic nerve disorder<sup>7</sup>, papilloedema<sup>8</sup>, oculogyric crisis,diplopia, scleritis, blepharitis</p></td><td style="vertical-align:top"><p>optic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atrophy, corneal opacity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top">Ear and labyrinth disorders</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">hypoacusis, vertigo, tinnitus</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/1,000 to &lt;</strong></p></td><td style="vertical-align:top"><p><strong>&ge; 1/10,000 to &lt;</strong></p></td><td style="vertical-align:top"><p><strong>not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>1/100</strong></p></td><td style="vertical-align:top"><p><strong>1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>(cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arrhythmia supraventricular, tachycardia, bradycardia</p></td><td style="vertical-align:top"><p>ventricular fibrillation, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, supraventricular</p><p>tachycardia</p></td><td style="vertical-align:top"><p>torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension, phlebitis</p></td><td style="vertical-align:top"><p>thrombophlebitis, lymphangitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>respiratory distress<sup>9</sup></p></td><td style="vertical-align:top"><p>acute respiratory distress syndrome, pulmonary oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestin al disorders</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>cheilitis, dyspepsia, constipation, gingivitis</p></td><td style="vertical-align:top"><p>peritonitis, pancreatitis, swollen tongue, duodenitis, gastroenteritis,</p><p>glossitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>liver function test abnormal</p></td><td style="vertical-align:top"><p>jaundice, jaundice cholestatic, hepatitis<sup>10</sup></p></td><td style="vertical-align:top"><p>hepatic failure, hepatomegaly, cholecystitis,</p><p>cholelithiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>dermatitis exfoliative, alopecia, rash maculo-papular, pruritus, erythema</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, phototoxicity, purpura, urticaria, dermatitis allergic, rash papular, rash macular, eczema</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, angioedema, actin keratosis<sup>*</sup>, pseudoporphyria, erythema multiforme,</p><p>psoriasis, drug</p></td><td style="vertical-align:top"><p>cutaneous lupus erythemato sus*, ephelides*, lentigo*</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Musculoskelet al and connective tissue</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>arthritis</p></td><td style="vertical-align:top"><p>eruption</p></td><td style="vertical-align:top"><p>periostitis*</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure acute, haematuria</p></td><td style="vertical-align:top"><p>renal tubular necrosis, proteinuria, nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration</p><p>site conditions</p></td><td style="vertical-align:top"><p>pyrexia</p></td><td style="vertical-align:top"><p>chest pain, face oedema<sup>11</sup>, asthenia, chills</p></td><td style="vertical-align:top"><p>infusion&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site reaction, influenza&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; like</p><p>illness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>&ge; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to</strong></p><p><strong>&lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to &lt;</strong></p><p><strong>1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge; 1/10,000 to &lt;</strong></p><p><strong>1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blood creatinine increased</p></td><td style="vertical-align:top"><p>blood urea increased, blood cholesterol increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*ADR identified post-marketing</p><p>1 Includes febrile neutropenia and neutropenia. 2 Includes immune thrombocytopenic purpura. 3 Includes nuchal rigidity and tetany.</p><p>4Includes hypoxic-ischaemic encephalopathy and metabolic encephalopathy.</p><p>5Includes akathisia and parkinsonism.</p><p>6See &ldquo;Visual impairments&rdquo; paragraph in section 4.8.</p><p>7Prolonged optic neuritis has been reported post-marketing. See section 4.4.</p><p>8See section 4.4.</p><p>9Includes dyspnoea and dyspnoea exertional.</p><p>10Includes drug-induced liver injury, hepatitis toxic, hepatocellular injury and hepatotoxicity.</p><p>11Includes periorbital oedema, lip oedema, and oedema mouth.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Visual impairments</em></p><p>In clinical trials, visual impairments (including blurred vision, photophobia, chloropsia, chromatopsia, colour blindness, cyanopsia, eye disorder, halo vision, night blindness, oscillopsia, photopsia, scintillating scotoma, visual acuity reduced, visual brightness, visual field defect, vitreous floaters, and xanthopsia) with voriconazole were very common. These visual impairments were transient and fully reversible, with the majority spontaneously resolving within 60 minutes and no clinically significant long-term visual effects were observed. There was evidence of attenuation with repeated doses of voriconazole. The visual impairments were generally mild, rarely resulted in discontinuation and were not associated with long-term sequelae. Visual impairments may be associated with higher plasma concentrations and/or doses.</p><p>The mechanism of action is unknown, although the site of action is most likely to be within the retina. In a study in healthy volunteers investigating the impact of voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude. The ERG measures electrical currents in the retina. The ERG changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.</p><p>There have been post-marketing reports of prolonged visual adverse events (see section 4.4).</p><p>&nbsp;</p><p><em>Dermatological reactions</em></p><p>Dermatological reactions were very common in patients treated with voriconazole in clinical trials, but these patients had serious underlying diseases and were receiving multiple concomitant medicinal products. The majority of rashes were of mild to moderate severity. Patients have developed serious cutaneous reactions, including Stevens-Johnson syndrome (uncommon), toxic epidermal necrolysis (rare) and erythema multiforme (rare) during treatment with voriconazole.</p><p>&nbsp;</p><p>If a patient develops a rash they should be monitored closely and voriconazole discontinued if lesions progress. Photosensitivity reactions such as ephelides, lentigo and actinic keratosis have been reported, especially during long-term therapy (see section 4.4).</p><p>&nbsp;</p><p>There have been reports of squamous cell carcinoma of the skin in patients treated with voriconazole for long periods of time; the mechanism has not been established (see section 4.4).</p><p>&nbsp;</p><p><em>Liver function tests</em></p><p>The overall incidence of transaminase increases &gt;3 xULN (not necessarily comprising an adverse event) in the voriconazole clinical programme was 18.0% (319/1,768) in adults and 25.8% (73/283) in paediatric subjects who received voriconazole for pooled therapeutic and prophylaxis use. Liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.</p><p>Voriconazole has been associated with cases of serious hepatic toxicity in patients with other serious underlying conditions. This includes cases of jaundice, hepatitis and hepatic failure leading to death (see section 4.4).</p><p>&nbsp;</p><p><em>Infusion-related reactions</em></p><p>During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnoea, faintness, nausea, pruritus and rash have occurred. Symptoms appeared immediately upon initiating the infusion (see section 4.4).</p><p>&nbsp;</p><p><em>Prophylaxis</em></p><p>In an open-label, comparative, multicenter study comparing voriconazole and itraconazole as primary prophylaxis in adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI, permanent discontinuation of voriconazole due to AEs was reported in 39.3% of subjects versus 39.6% of subjects in the itraconazole arm. Treatment-emergent hepatic AEs resulted in permanent discontinuation of study medication for 50 subjects (21.4%) treated with voriconazole and for 18 subjects (7.1%) treated with itraconazole.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety of voriconazole was investigated in 288 paediatric patients aged 2 to &lt;12 years (169) and 12 to</p><p>&lt;18 years (119) who received voriconazole for prophylaxis (183) and therapeutic use (105) in clinical trials. The safety of voriconazole was also investigated in 158 additional paediatric patients aged 2 to &lt;12 years in compassionate use programs. Overall, the safety profile of voriconazole in paediatric population was similar to that in adults. However, a trend towards a higher frequency of liver enzyme elevations, reported as adverse events in clinical trials was observed in paediatric patients as compared to adults (14.2% transaminases increased in paediatrics compared to 5.3% in adults). Post-marketing data suggest there might be a higher occurrence of skin reactions (especially erythema) in the paediatric population compared to adults. In the 22 patients less than 2 years old who received voriconazole in a compassionate use programme, the following adverse reactions (for which a relationship to voriconazole could not be excluded) were reported: photosensitivity reaction (1), arrhythmia (1), pancreatitis (1), blood bilirubin increased (1), hepatic enzymes increased (1), rash (1) and papilloedema (1). There have been postmarketing reports of pancreatitis in paediatric patients.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical trials there were 3 cases of accidental overdose. All occurred in paediatric patients, who received up to five times the recommended intravenous dose of voriconazole. A single adverse reaction of photophobia of 10 minutes duration was reported.</p><p>There is no known antidote to voriconazole.</p><p>Voriconazole is haemodialysed with a clearance of 121 ml/min. The intravenous vehicle, Betadex Sulfobutyl Ether Sodium, is haemodialysed with a clearance of 55 ml/min. In an overdose, haemodialysis may assist in the removal of voriconazole and Betadex Sulfobutyl Ether Sodium from the body.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02A C03</p><p>&nbsp;</p><p><u>Mode of Action</u></p><p>Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of voriconazole. Voriconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic Relationship</u></p><p>In 10 therapeutic studies, the median for the average and maximum plasma concentrations in individual subjects across the studies was 2425 ng/ml (inter-quartile range 1193 to 4380 ng/ml) and 3742 ng/ml (inter- quartile range 2027 to 6302 ng/ml), respectively. A positive association between mean, maximum or minimum plasma voriconazole concentration and efficacy in therapeutic studies was not found and this relationship has not been explored in prophylaxis studies.</p><p>&nbsp;</p><p>Pharmacokinetic-Pharmacodynamic analyses of clinical trial data identified positive associations between plasma voriconazole concentrations and both liver function test abnormalities and visual disturbances. Dose adjustments in prophylaxis studies have not been explored.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>In vitro</em>, voriconazole displays broad-spectrum antifungal activity with antifungal potency against <em>Candida </em>species (including fluconazole -resistant <em>C. krusei </em>and resistant strains of <em>C. glabrata </em>and <em>C. albicans</em>) and fungicidal activity against all <em>Aspergillus </em>species tested. In addition, voriconazole shows <em>in vitro </em>fungicidal activity against emerging fungal pathogens, including those such as <em>Scedosporium </em>or <em>Fusarium </em>which have limited susceptibility to existing antifungal agents.</p><p>&nbsp;</p><p>Clinical efficacy defined as partial or complete response, has been demonstrated for <em>Aspergillus </em>spp. including</p><p><em>A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans; Candida </em>spp.<em>, </em>including <em>C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis; </em>and limited numbers of <em>C. dubliniensis, C. inconspicua, </em>and <em>C. guilliermondii, Scedosporium </em>spp., including <em>S. apiospermum, S. prolificans; </em>and <em>Fusarium </em>spp.</p><p>&nbsp;</p><p>Other treated fungal infections (often with either partial or complete response) included isolated cases of <em>Alternaria </em>spp., <em>Blastomyces dermatitidis, Blastoschizomyces capitatus, Cladosporium </em>spp<em>., Coccidioides immitis, Conidiobolus coronatus, Cryptococcus neoformans, Exserohilum rostratum, Exophiala spinifera, Fonsecaea pedrosoi, Madurella mycetomatis, Paecilomyces lilacinus, Penicillium spp. including P.</em></p><p>&nbsp;</p><p><em>marneffei, Phialophora richardsiae, Scopulariopsis brevicaulis and Trichosporon </em>spp. including <em>T. beigelii</em></p><p>infections.</p><p>&nbsp;</p><p><em>In vitro </em>activity against clinical isolates has been observed for <em>Acremonium </em>spp., <em>Alternaria </em>spp., <em>Bipolaris </em>spp<em>., Cladophialophora </em>spp.<em>, </em>and <em>Histoplasma capsulatum, </em>with most strains being inhibited by concentrations of voriconazole in the range 0.05 to 2 &micro;g/ml.</p><p>&nbsp;</p><p><em>In vitro </em>activity against the following pathogens has been shown, but the clinical significance is unknown:</p><p><em>Curvularia </em>spp. and <em>Sporothrix </em>spp.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.</p><p>&nbsp;</p><p>The species most frequently involved in causing human infections include <em>C. albicans, C. parapsilosis, C. tropicalis, C. glabrata </em>and <em>C. krusei</em>, all of which usually exhibit minimal inhibitory concentration (MICs) of less than 1 mg/L for voriconazole.</p><p>&nbsp;</p><p>However, the <em>in vitro </em>activity of voriconazole against <em>Candida </em>species is not uniform. Specifically, for <em>C. glabrata, </em>the MICs of voriconazole for fluconazole-resistant isolates are proportionally higher than are those of fluconazole-susceptible isolates. Therefore, every attempt should be made to identify <em>Candida </em>to species level. If antifungal susceptibility testing is available, the MIC results may be interpreted using breakpoint criteria established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><p><u>EUCAST Breakpoints</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Candida species</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>MIC breakpoint (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&le;S (Susceptible)</strong></p></td><td style="vertical-align:top"><p><strong>&gt;R (Resistant)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Candida albicans<strong><sup>1</sup></strong></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida tropicalis<strong><sup>1</sup></strong></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida parapsilosis<strong><sup>1</sup></strong></em></p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.125</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida glabrata<strong><sup>2</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Candida krusei<strong><sup>3</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td style="vertical-align:top"><p><em>Other Candida spp.<strong><sup>4</sup></strong></em></p></td><td colspan="2" style="vertical-align:top"><p>Insufficient evidence</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Strains with MIC values above the Susceptible (S) breakpoint are rare, or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory.</p><p><strong><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>In clinical studies, response to voriconazole in patients with <em>C. glabrata </em>infections was 21% lower compared to <em>C. albicans</em>, <em>C. parapsilosis </em>and <em>C. tropicalis</em>. <em>In vitro </em>data showed a slight increase of resistance of <em>C. glabrata </em>to voriconazole.</p><p><strong><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>In clinical studies, response to voriconazole in <em>C. krusei </em>infections was similar to <em>C. albicans</em>, <em>C. parapsilosis </em>and <em>C. tropicalis</em>. However, as there were only 9 cases available for EUCAST analysis, there is currently insufficient evidence to set clinical breakpoints for <em>C. krusei</em>.</p><p><strong><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>EUCAST has not determined non-species related breakpoints for voriconazole.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Clinical experience</u></p><p>Successful outcome in this section is defined as complete or partial response.</p><p>&nbsp;</p><p><em><u>Aspergillus </u></em><u>infections &ndash; efficacy in aspergillosis patients with poor prognosis</u></p><p>Voriconazole has <em>in vitro </em>fungicidal activity against <em>Aspergillus </em>spp. The efficacy and survival benefit of voriconazole versus conventional amphotericin B in the primary treatment of acute invasive aspergillosis was demonstrated in an open, randomised, multicentre study in 277 immunocompromised patients treated for 12 weeks. Voriconazole was administered intravenously with a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours for a minimum of 7 days. Therapy could then be switched to the oral formulation at a dose of 200 mg every 12 hours. Median duration of IV voriconazole therapy was 10 days (range 2-85 days). After IV voriconazole therapy, the median duration of oral voriconazole therapy was 76 days (range 2-232 days).</p><p>&nbsp;</p><p>A satisfactory global response (complete or partial resolution of all attributable symptoms, signs, radiographic/bronchoscopic abnormalities present at baseline) was seen in 53% of voriconazole-treated patients compared to 31% of patients treated with comparator. The 84-day survival rate for voriconazole was statistically significantly higher than that for the comparator and a clinically and statistically significant benefit was shown in favour of voriconazole for both time to death and time to discontinuation due to toxicity.</p><p>&nbsp;</p><p>This study confirmed findings from an earlier, prospectively designed study where there was a positive outcome in subjects with risk factors for a poor prognosis, including graft versus host disease, and, in particular, cerebral infections (normally associated with almost 100% mortality).</p><p>&nbsp;</p><p>The studies included cerebral, sinus, pulmonary and disseminated aspergillosis in patients with bone marrow and solid organ transplants, haematological malignancies, cancer and AIDS.</p><p>&nbsp;</p><p><u>Candidaemia in non-neutropenic patients</u></p><p>The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study. Three hundred and seventy non-neutropenic patients (above 12 years of age) with documented candidaemia were included in the study, of whom 248 were treated with voriconazole. Nine subjects in the voriconazole group and 5 in the amphotericin B followed by fluconazole group also had mycologically proven infection in deep tissue. Patients with renal failure were excluded from this study. The median treatment duration was 15 days in both treatment arms. In the primary analysis, successful response as assessed by a Data Review Committee (DRC) blinded to study medicinal product was defined as resolution/improvement in all clinical signs and symptoms of infection with eradication of <em>Candida </em>from blood and infected deep tissue sites 12 weeks after the end of therapy (EOT). Patients who did not have an assessment 12 weeks after EOT were counted as failures. In this analysis a successful response was seen in 41% of patients in both treatment arms.</p><p>&nbsp;</p><p>In a secondary analysis, which utilised DRC assessments at the latest evaluable time point (EOT, or 2, 6, or 12 weeks after EOT) voriconazole and the regimen of amphotericin B followed by fluconazole had successful response rates of 65% and 71%, respectively.</p><p>&nbsp;</p><p>The Investigator&rsquo;s assessment of successful outcome at each of these time points is shown in the following table.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Timepoint</em></strong></p></td><td style="vertical-align:top"><p><strong><em>Voriconazole</em></strong></p><p>(N=248)</p></td><td style="vertical-align:top"><p><strong><em>Amphotericin B</em></strong></p><p><strong><em>&rarr; fluconazole</em></strong></p><p>(N=122)</p></td></tr><tr><td style="vertical-align:top"><p>EOT</p></td><td style="vertical-align:top"><p>178 (72%)</p></td><td style="vertical-align:top"><p>88 (72%)</p></td></tr><tr><td style="vertical-align:top"><p>2 weeks after EOT</p></td><td style="vertical-align:top"><p>125 (50%)</p></td><td style="vertical-align:top"><p>62 (51%)</p></td></tr><tr><td style="vertical-align:top"><p>6 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>55 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>12 weeks after EOT</p></td><td style="vertical-align:top"><p>104 (42%)</p></td><td style="vertical-align:top"><p>51 (42%)</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Serious refractory <em>Candida </em>infections</u></p><p>The study comprised 55 patients with serious refractory systemic <em>Candida </em>infections (including candidaemia, disseminated and other invasive candidiasis) where prior antifungal treatment, particularly with fluconazole, had been ineffective. Successful response was seen in 24 patients (15 complete, 9 partial responses). In fluconazole-resistant non-<em>albicans </em>species, a successful outcome was seen in 3/3 <em>C. krusei </em>(complete responses) and 6/8 <em>C. glabrata </em>(5 complete, 1 partial response) infections. The clinical efficacy data were supported by limited susceptibility data.</p><p>&nbsp;</p><p><em><u>Scedosporium </u></em><u>and <em>Fusarium </em>infections</u></p><p>Voriconazole was shown to be effective against the following rare fungal pathogens:</p><p>&nbsp;</p><p><em>Scedosporium </em>spp.: Successful response to voriconazole therapy was seen in 16 (6 complete, 10 partial responses) of 28 patients with <em>S. apiospermum </em>and in 2 (both partial responses) of 7 patients with</p><p><em>S. prolificans </em>infection. In addition, a successful response was seen in 1 of 3 patients with infections caused by more than one organism including <em>Scedosporium </em>spp.</p><p>&nbsp;</p><p><em>Fusarium </em>spp.: Seven (3 complete, 4 partial responses) of 17 patients were successfully treated with voriconazole. Of these 7 patients, 3 had eye, 1 had sinus, and 3 had disseminated infection. Four additional patients with fusariosis had an infection caused by several organisms; 2 of them had a successful outcome.</p><p>&nbsp;</p><p>The majority of patients receiving voriconazole treatment of the above mentioned rare infections were intolerant of, or refractory to, prior antifungal therapy.</p><p>&nbsp;</p><p><u>Primary Prophylaxis of Invasive Fungal Infections &ndash; Efficacy in HSCT recipients without prior proven or</u> <u>probable IFI</u></p><p>Voriconazole was compared to itraconazole as primary prophylaxis in an open-label, comparative, multicenter study of adult and adolescent allogeneic HSCT recipients without prior proven or probable IFI. Success was defined as the ability to continue study drug prophylaxis for 100 days after HSCT (without stopping for &gt;14 days) and survival with no proven or probable IFI for 180 days after HSCT. The modified intent-to-treat (MITT) group included 465 allogeneic HSCT recipients with 45% of patients having AML. From all patients 58% were subject to myeloablative conditions regimens. Prophylaxis with study drug was started immediately after HSCT: 224 received voriconazole and 241 received itraconazole. The median duration of study drug prophylaxis was 96 days for voriconazole and 68 days for itraconazole in the MITT group.</p><p>&nbsp;</p><p>Success rates and other secondary endpoints are presented in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole N=224</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole N=241</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence</strong></p><p><strong>interval (CI)</strong></p></td><td style="vertical-align:top"><p><strong>P-Value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Success at day 180*</p></td><td style="vertical-align:top"><p>109 (48.7%)</p></td><td style="vertical-align:top"><p>80 (33.2%)</p></td><td style="vertical-align:top"><p>16.4% (7.7%, 25.1%)**</p></td><td style="vertical-align:top"><p>0.0002**</p></td></tr><tr><td style="vertical-align:top"><p>Success at day 100</p></td><td style="vertical-align:top"><p>121 (54.0%)</p></td><td style="vertical-align:top"><p>96 (39.8%)</p></td><td style="vertical-align:top"><p>15.4% (6.6%, 24.2%)**</p></td><td style="vertical-align:top"><p>0.0006**</p></td></tr><tr><td style="vertical-align:top"><p>Completed at least 100 days of</p><p>study drug prophylaxis</p></td><td style="vertical-align:top"><p>120 (53.6%)</p></td><td style="vertical-align:top"><p>94 (39.0%)</p></td><td style="vertical-align:top"><p>14.6% (5.6%, 23.5%)</p></td><td style="vertical-align:top"><p>0.0015</p></td></tr><tr><td style="vertical-align:top"><p>Survived to day 180</p></td><td style="vertical-align:top"><p>184 (82.1%)</p></td><td style="vertical-align:top"><p>197 (81.7%)</p></td><td style="vertical-align:top"><p>0.4% (-6.6%, 7.4%)</p></td><td style="vertical-align:top"><p>0.9107</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI</p><p>to day 180</p></td><td style="vertical-align:top"><p>3 (1.3%)</p></td><td style="vertical-align:top"><p>5 (2.1%)</p></td><td style="vertical-align:top"><p>-0.7% (-3.1%, 1.6%)</p></td><td style="vertical-align:top"><p>0.5390</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI</p><p>to day 100</p></td><td style="vertical-align:top"><p>2 (0.9%)</p></td><td style="vertical-align:top"><p>4 (1.7%)</p></td><td style="vertical-align:top"><p>-0.8% (-2.8%, 1.3%)</p></td><td style="vertical-align:top"><p>0.4589</p></td></tr><tr><td style="vertical-align:top"><p>Developed proven or probable IFI</p><p>while on study drug</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>3 (1.2%)</p></td><td style="vertical-align:top"><p>-1.2% (-2.6%, 0.2%)</p></td><td style="vertical-align:top"><p>0.0813</p></td></tr></tbody></table><p>* Primary endpoint of the study</p><p>** Difference in proportions, 95% CI and p-values obtained after adjustment for randomization</p><p>&nbsp;</p><p>The breakthrough IFI rate to Day 180 and the primary endpoint of the study, which is Success at Day 180, for patients with AML and myeloablative conditioning regimens respectively, is presented in the table below:</p><p>&nbsp;</p><p>AML</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole (N=98)</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole (N=109)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and</strong></p><p><strong>the 95% confidence interval (CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>1 (1.0%)</p></td><td style="vertical-align:top"><p>2 (1.8%)</p></td><td style="vertical-align:top"><p>-0.8% (-4.0%, 2.4%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>55 (56.1%)</p></td><td style="vertical-align:top"><p>45 (41.3%)</p></td><td style="vertical-align:top"><p>14.7% (1.7%, 27.7%)***</p></td></tr></tbody></table><p>* Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>***Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p>Myeloablative conditioning regimens</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Voriconazole (N=125)</strong></p></td><td style="vertical-align:top"><p><strong>Itraconazole (N=143)</strong></p></td><td style="vertical-align:top"><p><strong>Difference in proportions and the 95% confidence interval</strong></p><p><strong>(CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Breakthrough IFI &ndash; Day 180</p></td><td style="vertical-align:top"><p>2 (1.6%)</p></td><td style="vertical-align:top"><p>3 (2.1%)</p></td><td style="vertical-align:top"><p>-0.5% (-3.7%, 2.7%) **</p></td></tr><tr><td style="vertical-align:top"><p>Success at Day 180*</p></td><td style="vertical-align:top"><p>70 (56.0%)</p></td><td style="vertical-align:top"><p>53 (37.1%)</p></td><td style="vertical-align:top"><p>20.1% (8.5%, 31.7%)***</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; Primary endpoint of study</p><p>** Using a margin of 5%, non inferiority is demonstrated</p><p>*** Difference in proportions, 95% CI obtained after adjustment for randomization</p><p>&nbsp;</p><p><u>Secondary Prophylaxis of IFI &ndash; Efficacy in HSCT recipients with prior proven or probable IFI</u></p><p>Voriconazole was investigated as secondary prophylaxis in an open-label, non-comparative, multicenter study of adult allogeneic HSCT recipients with prior proven or probable IFI. The primary endpoint was the rate of occurrence of proven and probable IFI during the first year after HSCT. The MITT group included 40 patients with prior IFI, including 31 with aspergillosis, 5 with candidiasis, and 4 with other IFI. The median duration of study drug prophylaxis was 95.5 days in the MITT group.</p><p>&nbsp;</p><p>Proven or probable IFIs developed in 7.5% (3/40) of patients during the first year after HSCT, including one candidemia, one scedosporiosis (both relapses of prior IFI), and one zygomycosis. The survival rate at Day 180 was 80.0% (32/40) and at 1 year was 70.0% (28/40).</p><p>&nbsp;</p><p><u>Duration of treatment</u></p><p>In clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164 patients receiving voriconazole for over 6 months.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Fifty-three paediatric patients aged 2 to &lt;18 years were treated with voriconazole in two prospective, open- label, non-comparative, multi-center clinical trials. One study enrolled 31 patients with possible, proven or probable invasive aspergillosis (IA), of whom 14 patients had proven or probable IA and were included in the MITT efficacy analyses. The second study enrolled 22 patients with invasive candidiasis including candidaemia (ICC), and esophageal candidiasis (EC) requiring either primary or salvage therapy, of whom 17 were included in the MITT efficacy analyses. For patients with IA the overall rates of global response at 6 weeks were 64.3% (9/14), the global response rate was 40% (2/5) for patients 2 to &lt;12 years and 77.8% (7/9) for patients 12 to &lt;18 years of age. For patients with ICC the global response rate at EOT was 85.7% (6/7) and for patients with EC the global response rate at EOT was 70% (7/10). The overall rate of response (ICC and EC combined) was 88.9% (8/9) for 2 to &lt;12 years old and 62.5% (5/8) for 12 to &lt;18 years old.</p><p>&nbsp;</p><p><u>Clinical studies examining QTc interval</u></p><p>A placebo-controlled, randomized, single-dose, crossover study to evaluate the effect on the QTc interval of healthy volunteers was conducted with three oral doses of voriconazole and ketoconazole. The placebo- adjusted mean maximum increases in QTc from baseline after 800, 1200 and 1600 mg of voriconazole were 5.1, 4.8, and 8.2 msec, respectively and 7.0 msec for ketoconazole 800 mg. No subject in any group had an increase in QTc of &ge; 60 msec from baseline. No subject experienced an interval exceeding the potentially clinically-relevant threshold of 500 msec.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General pharmacokinetic characteristics</u></p><p>The pharmacokinetics of voriconazole have been characterised in healthy subjects, special populations and patients. During oral administration of 200 mg or 300 mg twice daily for 14 days in patients at risk of aspergillosis (mainly patients with malignant neoplasms of lymphatic or haematopoietic tissue), the observed pharmacokinetic characteristics of rapid and consistent absorption, accumulation and non-linear pharmacokinetics were in agreement with those observed in healthy subjects.</p><p>&nbsp;</p><p>The pharmacokinetics of voriconazole are non-linear due to saturation of its metabolism. Greater than proportional increase in exposure is observed with increasing dose. It is estimated that, on average, increasing the oral dose from 200 mg twice daily to 300 mg twice daily leads to a 2.5-fold increase in exposure (AUC&tau;). The oral maintenance dose of 200 mg (or 100 mg for patients less than 40 kg) achieves a voriconazole exposure similar to 3 mg/kg IV. A 300 mg (or 150 mg for patients less than 40 kg) oral maintenance dose achieves an exposure similar to 4 mg/kg IV. When the recommended intravenous or oral loading dose regimens are administered, plasma concentrations close to steady state are achieved within the first 24 hours of dosing. Without the loading dose, accumulation occurs during twice daily multiple dosing with steady-state plasma voriconazole concentrations being achieved by Day 6 in the majority of subjects.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Voriconazole is rapidly and almost completely absorbed following oral administration, with maximum plasma concentrations (Cmax) achieved 1-2 hours after dosing. The absolute bioavailability of voriconazole after oral administration is estimated to be 96%. When multiple doses of voriconazole are administered with high fat meals, Cmax and AUC&tau; are reduced by 34% and 24%, respectively. The absorption of voriconazole is not affected by changes in gastric pH.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution at steady state for voriconazole is estimated to be 4.6 L/kg, suggesting extensive distribution into tissues. Plasma protein binding is estimated to be 58%.</p><p>&nbsp;</p><p>Cerebrospinal fluid samples from eight patients in a compassionate programme showed detectable voriconazole concentrations in all patients.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>In vitro </em>studies showed that voriconazole is metabolised by the hepatic cytochrome P450 isoenzymes CYP2C19, CYP2C9 and CYP3A4.</p><p>&nbsp;</p><p>The inter-individual variability of voriconazole pharmacokinetics is high.</p><p>&nbsp;</p><p><em>In vivo </em>studies indicated that CYP2C19 is significantly involved in the metabolism of voriconazole. This enzyme exhibits genetic polymorphism. For example, 15-20% of Asian populations may be expected to be poor metabolisers. For Caucasians and Blacks the prevalence of poor metabolisers is 3-5%. Studies conducted in Caucasian and Japanese healthy subjects have shown that poor metabolisers have, on average, 4-fold higher voriconazole exposure (AUC&tau;) than their homozygous extensive metaboliser counterparts. Subjects who are heterozygous extensive metabolisers have on average 2-fold higher voriconazole exposure than their homozygous extensive metaboliser counterparts.</p><p>&nbsp;</p><p>The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. This metabolite has minimal antifungal activity and does not contribute to the overall efficacy of voriconazole.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.</p><p>&nbsp;</p><p>After administration of a radiolabelled dose of voriconazole, approximately 80% of the radioactivity is recovered in the urine after multiple intravenous dosing and 83% in the urine after multiple oral dosing. The majority (&gt;94%) of the total radioactivity is excreted in the first 96 hours after both oral and intravenous dosing.</p><p>&nbsp;</p><p>The terminal half-life of voriconazole depends on dose and is approximately 6 hours at 200 mg (orally). Because of non-linear pharmacokinetics, the terminal half-life is not useful in the prediction of the accumulation or elimination of voriconazole.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p><em>Gender</em></p><p>In an oral multiple-dose study, Cmax and AUC&tau; for healthy young females were 83% and 113% higher, respectively, than in healthy young males (18-45 years)<em>. </em>In the same study, no significant differences in Cmax and AUC&tau; were observed between healthy elderly males and healthy elderly females (&ge;65 years).</p><p>&nbsp;</p><p>In the clinical programme, no dosage adjustment was made on the basis of gender. The safety profile and plasma concentrations observed in male and female patients were similar. Therefore, no dosage adjustment based on gender is necessary.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In an oral multiple-dose study Cmax and AUC&tau; in healthy elderly males (&ge;65 years) were 61% and 86% higher, respectively, than in healthy young males (18-45 years). No significant differences in Cmax and AUC&tau; were observed between healthy elderly females (&ge;65 years) and healthy young females (18-45 years).</p><p>&nbsp;</p><p>In the therapeutic studies no dosage adjustment was made on the basis of age. A relationship between plasma concentrations and age was observed. The safety profile of voriconazole in young and elderly patients was similar and, therefore, no dosage adjustment is necessary for the elderly (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The recommended doses in children and adolescent patients are based on a population pharmacokinetic analysis of data obtained from 112 immunocompromised paediatric patients aged 2 to &lt;12 years and 26 immunocompromised adolescent patients aged 12 to &lt;17 years. Multiple intravenous doses of 3, 4, 6, 7 and 8 mg/kg twice daily and multiple oral doses (using the powder for oral suspension) of 4 mg/kg, 6 mg/kg, and 200 mg twice daily were evaluated in 3 paediatric pharmacokinetic studies. Intravenous loading doses of 6 mg/kg IV twice daily on day 1 followed by 4 mg/kg intravenous dose twice daily and 300 mg oral tablets twice daily were evaluated in one adolescent pharmacokinetic study. Larger inter-subject variability was observed in paediatric patients compared to adults.</p><p>&nbsp;</p><p>A comparison of the paediatric and adult population pharmacokinetic data indicated that the predicted total exposure (AUC&tau;) in children following administration of a 9 mg/kg IV loading dose was comparable to that in adults following a 6 mg/kg IV loading dose. The predicted total exposures in children following IV maintenance doses of 4 and 8 mg/kg twice daily were comparable to those in adults following 3 and 4 mg/kg IV twice daily, respectively. The predicted total exposure in children following an oral maintenance dose of 9 mg/kg (maximum of 350 mg) twice daily was comparable to that in adults following 200 mg oral twice</p><p>&nbsp;</p><p>daily. An 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.</p><p>&nbsp;</p><p>The higher intravenous maintenance dose in paediatric patients relative to adults reflects the higher elimination capacity in paediatric patients due to a greater liver mass to body mass ratio. Oral bioavailability may, however, be limited in paediatric patients with malabsorption and very low body weight for their age. In that case, intravenous voriconazole administration is recommended.</p><p>&nbsp;</p><p>Voriconazole exposures in the majority of adolescent patients were comparable to those in adults receiving the same dosing regimens. However, lower voriconazole exposure was observed in some young adolescents with low body weight compared to adults. It is likely that these subjects may metabolize voriconazole more similarly to children than to adolescents/adults. Based on the population pharmacokinetic analysis, 12- to 14- year-old adolescents weighing less than 50 kg should receive children&rsquo;s doses (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with moderate to severe renal dysfunction (serum creatinine levels &gt; 2.5 mg/dl), accumulation of the intravenous vehicle, Betadex Sulfobutyl Ether Sodium, occurs (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>After an oral single-dose (200 mg), AUC was 233% higher in subjects with mild to moderate hepatic cirrhosis (Child-Pugh A and B) compared with subjects with normal hepatic function. Protein binding of voriconazole was not affected by impaired hepatic function.</p><p>&nbsp;</p><p>In&nbsp;an&nbsp;oral&nbsp;multiple-dose&nbsp;study,&nbsp;AUC&tau; was similar in subjects with moderate hepatic cirrhosis (Child-Pugh B) given a maintenance dose of 100 mg twice daily and subjects with normal hepatic function given 200 mg twice daily. No pharmacokinetic data are available for patients with severe hepatic cirrhosis (Child-Pugh C) (see sections 4.2 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated-dose toxicity studies with voriconazole indicated the liver to be the target organ. Hepatotoxicity occurred at plasma exposures similar to those obtained at therapeutic doses in humans, in common with other antifungal agents. In rats, mice and dogs, voriconazole also induced minimal adrenal changes.</p><p>Conventional studies of safety pharmacology, genotoxicity or carcinogenic potential did not reveal a special hazard for humans.</p><p>&nbsp;</p><p>In reproduction studies, voriconazole was shown to be teratogenic in rats and embryotoxic in rabbits at systemic exposures equal to those obtained in humans with therapeutic doses. In the pre- and post-natal development study in rats at exposures lower than those obtained in humans with therapeutic doses, voriconazole prolonged the duration of gestation and labour and produced dystocia with consequent maternal mortality and reduced perinatal survival of pups. The effects on parturition are probably mediated by species- specific mechanisms, involving reduction of oestradiol levels, and are consistent with those observed with other azole antifungal agents. Voriconazole administration induced no impairment of male or female fertility in rats at exposures similar to those obtained in humans at therapeutic doses.</p><p>&nbsp;</p><p>Preclinical data on the intravenous vehicle Betadex Sulfobutyl Ether Sodium indicated that the main effects were vacuolation of urinary tract epithelium and activation of macrophages in the liver and lungs in the repeated-dose toxicity studies. As GPMT (guinea pig maximisation test) result was positive, prescribers should be aware of the hypersensitivity potential of the intravenous formulation. Standard genotoxicity and reproduction studies with the excipient Betadex Sulfobutyl Ether Sodium reveal no special hazard for humans. Carcinogenicity studies were not performed with Betadex Sulfobutyl Ether Sodium. An impurity present in Betadex Sulfobutyl Ether Sodium has been shown to be an alkylating mutagenic agent with evidence for carcinogenicity in rodents. This impurity should be considered a substance with carcinogenic</p><p>&nbsp;</p><p>potential in humans. In light of these data the duration of treatment with the intravenous formulation should be no longer than 6 months.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Betadex Sulfobutyl Ether Sodium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VORIC must not be infused into the same line or cannula concomitantly with other intravenous products. When the VORIC infusion is complete, the line may be used for administration of other intravenous products<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><u>Blood products and short-term infusion of concentrated solutions of electrolytes</u>: Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be corrected prior to initiation of voriconazole therapy (see sections 4.2 and 4.4). VORIC must not be administered simultaneously with any blood product or any short-term infusion of concentrated solutions of electrolytes, even if the two infusions are running in separate lines.</p><p>&nbsp;</p><p><u>Total parenteral nutrition: </u>Total parenteral nutrition (TPN) need <em>not </em>be discontinued when prescribed with VORIC, but does need to be infused through a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for VORIC. VORIC must not be diluted with 4.2% Sodium Bicarbonate Infusion. Compatibility with other concentrations is unknown.</p><p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

From a microbiological point of view, once reconstituted, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C (in a refrigerator).

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>50 ml clear Type I glass vial with bromobutyl rubber stopper and aluminum seal with blue, plastic flip-off cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>The powder is reconstituted with either 19 ml of water for injections or 19 ml of 9 mg/ml (0.9%) Sodium Chloride for Infusion to obtain an extractable volume of 20 ml of clear concentrate containing 10 mg/ml of voriconazole. Discard the VORIC vial if vacuum does not pull the diluent into the vial. It is recommended that a standard 20 ml (non-automated) syringe be used to ensure that the exact amount (19.0 ml) of water for injections or (9 mg/ml [0.9%]) Sodium Chloride for Infusion is dispensed. This medicinal product is for single use only and any unused solution should be discarded. Only clear solutions without particles should be used.</p><p>&nbsp;</p><p>For administration, the required volume of the reconstituted concentrate is added to a recommended compatible infusion solution (detailed in the table below) to obtain a final voriconazole solution containing 0.5- 5 mg/ml.</p><p>&nbsp;</p><p>The reconstituted solution can be diluted with:</p><p>&nbsp;</p><p>Sodium Chloride 9 mg/ml (0.9%) Solution for Injection Compound Sodium Lactate Intravenous Infusion 5% Glucose and Lactated Ringer&rsquo;s Intravenous Infusion</p><p>5% Glucose and 0.45% Sodium Chloride Intravenous Infusion 5% Glucose Intravenous Infusion</p><p>5% Glucose in 20 mEq Potassium Chloride Intravenous Infusion 0.45% Sodium Chloride Intravenous Infusion</p><p>5% Glucose and 0.9% Sodium Chloride Intravenous Infusion</p><p>&nbsp;</p><p>The compatibility of voriconazole with diluents other than described above or in section 6.2 is unknown.</p><p>&nbsp;</p><p><u>Required Volumes of 10 mg/ml Voriconazole Concentrate</u></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Body Weight (kg)</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Volume of Voriconazole Concentrate (10 mg/ml) required for:</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>3 mg/kg dose (number of vials)</strong></p></td><td style="vertical-align:top"><p><strong>4 mg/kg dose (number of</strong></p><p><strong>vials)</strong></p></td><td style="vertical-align:top"><p><strong>6 mg/kg dose (number of vials)</strong></p></td><td style="vertical-align:top"><p><strong>8 mg/kg dose (number of vials)</strong></p></td><td style="vertical-align:top"><p><strong>9 mg/kg dose (number of vials)</strong></p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4.0 ml (1)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>8.0 ml (1)</p></td><td style="vertical-align:top"><p>9.0 ml (1)</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>6.0 ml (1)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>12.0 ml (1)</p></td><td style="vertical-align:top"><p>13.5 ml (1)</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>8.0 ml (1)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>16.0 ml (1)</p></td><td style="vertical-align:top"><p>18.0 ml (1)</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>10.0 ml (1)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>20.0 ml (1)</p></td><td style="vertical-align:top"><p>22.5 ml (2)</p></td></tr><tr><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>9.0 ml (1)</p></td><td style="vertical-align:top"><p>12.0 ml (1)</p></td><td style="vertical-align:top"><p>18.0 ml (1)</p></td><td style="vertical-align:top"><p>24.0 ml (2)</p></td><td style="vertical-align:top"><p>27.0 ml (2)</p></td></tr><tr><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>10.5 ml (1)</p></td><td style="vertical-align:top"><p>14.0 ml (1)</p></td><td style="vertical-align:top"><p>21.0 ml (2)</p></td><td style="vertical-align:top"><p>28.0 ml (2)</p></td><td style="vertical-align:top"><p>31.5 ml (2)</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>12.0 ml (1)</p></td><td style="vertical-align:top"><p>16.0 ml (1)</p></td><td style="vertical-align:top"><p>24.0 ml (2)</p></td><td style="vertical-align:top"><p>32.0 ml (2)</p></td><td style="vertical-align:top"><p>36.0 ml (2)</p></td></tr><tr><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>13.5 ml (1)</p></td><td style="vertical-align:top"><p>18.0 ml (1)</p></td><td style="vertical-align:top"><p>27.0 ml (2)</p></td><td style="vertical-align:top"><p>36.0 ml (2)</p></td><td style="vertical-align:top"><p>40.5 ml (3)</p></td></tr><tr><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>15.0 ml (1)</p></td><td style="vertical-align:top"><p>20.0 ml (1)</p></td><td style="vertical-align:top"><p>30.0 ml (2)</p></td><td style="vertical-align:top"><p>40.0 ml (2)</p></td><td style="vertical-align:top"><p>45.0 ml (3)</p></td></tr><tr><td style="vertical-align:top"><p>55</p></td><td style="vertical-align:top"><p>16.5 ml (1)</p></td><td style="vertical-align:top"><p>22.0 ml (2)</p></td><td style="vertical-align:top"><p>33.0 ml (2)</p></td><td style="vertical-align:top"><p>44.0 ml (3)</p></td><td style="vertical-align:top"><p>49.5 ml (3)</p></td></tr><tr><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>18.0 ml (1)</p></td><td style="vertical-align:top"><p>24.0 ml (2)</p></td><td style="vertical-align:top"><p>36.0 ml (2)</p></td><td style="vertical-align:top"><p>48.0 ml (3)</p></td><td style="vertical-align:top"><p>54.0 ml (3)</p></td></tr><tr><td style="vertical-align:top"><p>65</p></td><td style="vertical-align:top"><p>19.5 ml (1)</p></td><td style="vertical-align:top"><p>26.0 ml (2)</p></td><td style="vertical-align:top"><p>39.0 ml (2)</p></td><td style="vertical-align:top"><p>52.0 ml (3)</p></td><td style="vertical-align:top"><p>58.5 ml (3)</p></td></tr><tr><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>21.0 ml (2)</p></td><td style="vertical-align:top"><p>28.0 ml (2)</p></td><td style="vertical-align:top"><p>42.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>22.5 ml (2)</p></td><td style="vertical-align:top"><p>30.0 ml (2)</p></td><td style="vertical-align:top"><p>45.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>80</p></td><td style="vertical-align:top"><p>24.0 ml (2)</p></td><td style="vertical-align:top"><p>32.0 ml (2)</p></td><td style="vertical-align:top"><p>48.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>25.5 ml (2)</p></td><td style="vertical-align:top"><p>34.0 ml (2)</p></td><td style="vertical-align:top"><p>51.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>90</p></td><td style="vertical-align:top"><p>27.0 ml (2)</p></td><td style="vertical-align:top"><p>36.0 ml (2)</p></td><td style="vertical-align:top"><p>54.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>28.5 ml (2)</p></td><td style="vertical-align:top"><p>38.0 ml (2)</p></td><td style="vertical-align:top"><p>57.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>30.0 ml (2)</p></td><td style="vertical-align:top"><p>40.0 ml (2)</p></td><td style="vertical-align:top"><p>60.0 ml (3)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Further information is provided for medical or healthcare professionals at the end of the Package Leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. Hail Industrial City MODON, Street No 32 PO Box 6979, Hail 55414
Kingdom of Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 October 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>